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SUMMARY
The effect of cytosine arabinoside on DNA synthesis in
Tetral./mena pyriformis has been studied. DNA synthesis was determined
3by measuring the incorporation of (methyl- H)thymidine into DNA. The 
DNA formed was analysed by sedimentation on alkaline sucrose gradients. 
In the presence of cytosine arabinoside labelled thymidine was 
incorporated into high molecular weight DNA. This indicates that in 
Tetrahymena, AraC inhibits the initiation steps of DNA synthesis but 
does not interfere with the elongation of DNA already formed.
Initial experiments indicated that Tetrahymena quickly recovered 
from the effect of AraC. The metabolites of AraC were analysed by ion • 
exchange chromatography. AraC was separated from AraCMP, AraCDP and 
AraCTP on the anion exchanger AG1-X8. AraC and AraU were separated on 
Dowex 50 or AG50-X8. It was found that whereas a large proportion of 
cellular AraC is converted to AraU only a small fraction is converted 
to AraCTP, the putative active agent in inhibiting DNA replication 
and causing cell death. In the presence of tetrahydrouridine AraC is 
not deaminated, but this did not lead to increased amounts of phos- 
phorylated products of AraC.
Two DNA polymerase fractions which differed in their sensitivity 
to NEM and AraCTP were prepared. The nuclear enzyme was resistant to 
NEM and was activated by AraCTP. The cytoplasmic enzyme was inhibited 
by both AraCTP and NEM. An attempt was made to fractionate Tetrahymena 
DNA polymerases on DEAE-cellulose. Two fractions A and B, which 
differed in their ability to use polyA.polydT as a template-primer 
were prepared. The correspondence of these to in vivo nuclear and 
cytoplasmic enzymes is not yet clear.
CHAPTER 1
1. DNA SYNTHESIS IN EUKARYOTES
1.1 Structure of the eukaryotic chromosome (1)
The DNA of eukaryotic cells is packaged in several chromosomes 
or chromatin where the DNA is closely associated with histones and 
other proteins. As DNA is duplicated the proper types and amounts 
of chromosomal proteins must be synthesized. DNA and histone 
synthesis are delicately controlled processes and are confined to 
the S phase of the cell cycle. There must be mechanisms to ensure 
that cellular DNA is replicated only once per cell cycle.
DNA and the nuclear proteins associated with it are called 
chromatin during the interphase stage of the cell and can be seen as 
chromosomes during the mitotic stages. Histones are the major 
proteins of eukaryotic chromosomes and chromatin. Most cells 
contain five different types of these basic proteins (3). The basic 
unit of chromatin, the nucleosome, is a roughly spherical body 
consisting of about 140 base pairs of coiled DNA (4), and an octamer 
comprising two molecules of each of the small histones, H2A, H2B, H3, 
and H4, which have a very conservative amino acid sequence (5). The 
precise arrangement of the four histones is not yet known. It has 
been suggested that the octamer forms by protein-protein interactions 
between individual histones involving the hydrophobic C-terminal 
halves of the histone molecules. The N-terminals would then be free 
to interact with the DNA on the outside (6).
Between nucleosomes is a stretch of DNA of between twenty to 
seventy base pairs. This section or linker may also be coiled. The 
role of the fifth histone, HI, is still unclear. Removal of this 
histone exposes the linker between nucleosomes to produce fibres
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2which look like a string of beads under the electron microscope.
Non-histone proteins are a heterogeneous group of acidic proteins 
which are thought to play structural, enzymatic and regulatory roles 
in chromatin. Some of these proteins may be involved in the trans­
port of mRNA from the nucleus to the cytoplasm.
Each chromosome is divided into many replication units or 
replicons of varying size. For each replication unit DNA synthesis 
begins at an origin and proceeds semiconservatively and bidirection­
ally. It is not clear whether origins are defined by specific 
nucleotide sequences. This type of replication produces the 
"bubbles" which can be seen under the electron microscope.
Unlike the size of replication units which depends on the stage 
of development of the cell, the rate of movement of the replication 
fork is similar for cells which are dividing rapidly and those 
dividing slowly. It appears that the rate of replication depends on 
the number of active replicating units at any time in the S phase.
1.2 Mechanism of DNA replication in eukaryotes.
It is generally accepted that the processes by which genet'c 
information is preserved and transmitted are essentially the same in 
eukaryotes and simpler organisms. Replication of DNA follows a semi­
conservative mechanism. Each strand of the DNA duplex is conserved 
and copied by base pairing with matching deoxynucleotides to yield 
two duplexes identical to the parental ones (7). In vitro the DNA 
polymerizing reaction requires a) a DNA template, b) a DNA or RNA 
primer with a free 3'hydroxyl end, c) the four deoxynucleotides dATP, 
dCTP, dGTP and dTTP and d) a metal ion such as magnesium. The reaction 
may be summarised as follows:
Figure 1.1
Schematic diagram showing the arrangement of DNA and histones
DNA is wound round histone octamers to form roughly spherical bodies 
at regular intervals. The spheres are separated by short segments 
of linker DNA to form a structure similar to a string of beads. The 
position of the histone HI is still unclear but it is thought to be 
in the region of the linker DNA segment.
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Although many models have been proposed for DNA replication none 
is completely adequate in accounting for all the known facts concerning 
the replication of double-stranded DNA (8). The process of DNA 
replication may be conveniently considered in terms of initiation, 
chain growth and termination. The model described below is essentially 
that proposed by Huberman and Riggs (2) and expanded by Hewish (10). 
1.2.1 Initiation
Although some details about the chemistry of the initiation of 
DNA synthesis have been elucidated little can be said about the factors 
which set the replication process in motion. It appears that at the 
beginning of DNA replication a DNA unwinding protein binds to single 
stranded DNA in such a way that RNA polymerase (primase) starts the 
synthesis of a new chain at a specific site on a single stranded DNA 
template (11, 12). Because of its specificity for single stranded 
DNA it is assumed that unwinding protein does not bind to double 
stranded DNA. It is proposed that the initiation site is on the 
relatively few sites between histone oligomers. The stretches of RNA, 
about ten nucleotides in length, synthesized as primers for Okazaki 
fragments by a specific primase, probably do not have a specific base 
sequence.
It has been shown that RNA polymerases are able to start new 
chains and that DNA polymerases can extend these chains in vivo (13) 
and in vitro (14). However, it has not been possible to identify RNA 
priming segments. This may be because of their inherently transitory
'
Figure 1.2
Bidirectional replication of DNA in eukaryotes
Each chromosome is thought to consist of several replication units 
each with its own origin. The beginning of chain replication does 
not necessarily occur at the same time for all the origins. Soon 
after initiation replication bubbles are formed. Within each bubble 
replication takes place bidirectionally at two forks.
(a) before replication
(b) after the initiation of DNA replication has started at two 
origins.
The bubble on the left started later than the one on the 
right.
(c) the fusion of adjacent bubbles to form a single growing 
bubble.
old DNA
newly formed DNA
The direction of replication is shown by the arrows.

Figure 1.3
Initiation of DNA replication
At the beginning of DNA replication the nucleosome structure must 
be undone to expose sites for DNA synthesis to start. After this 
the following events probably take place.
(A) RNA polymerase initiates priming at an accessible site.
(B) DNA synthesis starts from the formed RNA primer.
(C) Further initiation sites are exposed.
(D) Newly formed DNA chains are joined by a ligase. Further 
primers are started on the displaced strand. The original 
initiation site is blocked to further replication.
____________  DNA
____________ RNA
Histone complex
Blocking protein
The arrows show the direction of replication.
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1.2.2 Chain elongation (15)
DNA synthesis is initiated on RNA primers by a replicative DNA 
polymerase. It is thought that as DNA synthesis continues secondary 
sites for primer RNA synthesis become available on either side of the 
first initiation site.
Available evidence indicates that both daughter strands grow at 
the same time. The direction of synthesis is 3' to 5' on one strand 
and 5' to 3' on the other. However, no enzymic mechanism for extend­
ing DNA chains in a 3' to 5' direction has been demonstrated. There 
is increasing evidence that this problem is solved by synthesizing 
short stretches of DNA in a 5' to 3' direction (9). These segments, 
about ten nucleotides long, would then be joined to the growing 
polynucleotide by formation of phosphodiester linkages. The RNA 
segments have no unique base sequence but probably have a well defined 
size. All have pppA or ppG at their 5' end. The size of the 
initiator RNA may provide the signal for switching from RNA to DNA 
synthesis.
It seems that the synthesis of eukaryotic DNA occurs semidiscon- 
tinuously (16). Okazaki fragments are formed only on one of the 
daughter strands - the lagging strand. It appears that no Okazaki 
fragments are formed on the leading strand which replicates continuously.
The elongation reaction involves nucleophilic attack of the 3'
OH primer terminus upon the alpha phosphorus of a deoxynucleotide 
substrate with displacement of pyrophosphate (17). The following 
sequence of reactions probably takes place:
a) DNA polymerase binds DNA in a complex in which the 3'-hydroxy 
terminus of the strand is activated. The activation may be by co-ordi­
nation to enzyme-bound zinc. There is some evidence that zinc is
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involved in such a complex (18). It appears that added magnesium or 
manganese is not involved at this stage of the reaction.
b) In the second step the binding of the dNTP occurs by 
co-ordination of the alpha phosphoryl group to the enzyme bound 
divalent activator (Mn or Mg). Although magnesium is not essential 
for binding of the DNA template it is required for the binding of the 
nucleotide to the enzyme. Base pairing between the nucleotide to be 
polymerised and the template strand provides further stabilization.
c) In the next step there is a nucleophilic attack on the alpha 
phosphoryl group by the 3'-hydroxy group at the end of the primer 
strand. At the same time pyrophosphate is displaced. Zinc may 
facilitate the process by promoting deprotonation of the OH group in 
a mechanism similar to the zinc hydroxide mechanism proposed for 
carbonic anhydrase (19). Susceptibility of the alpha phosphoryl group 
to nucleophilic attack would be increased by co-ordination to Mn or
Mg which withdraw electrons and neutralize the positive charge. 
Nucleotidyl transfer is now complete and primer translocation begins.
d) As a new primer terminus appears water ligands substitute 
for the phosphodiester ligand on the enzyme-bound manganese or 
magnesium. Zinc dissociates from the 3' oxygen atom of the previous 
nucleotide and co-ordinates with the new 3'-hydroxyl group.
1.2.3. Termination
The final steps in DNA synthesis involve the excising of primer 
RNA, the joining of Okazaki fragments and restoration of the original 
chromatin structure. Primer RNA is removed by nucleases. The resulting 
gap is then filled by DNA polymerases. The short fragments are joined 
to form high molecular weight DNA by ligases (9). Restoration of the 
original chromatin structure and blocking of the initiation site 
prevent further replication cycles. Little is known about how these
12
Figure 1.4
The elongation of a DNA chain by a DNA polymerase in the presence of 
___________________________ template_______
(I) The enzyme binds DNA. The 3'-hydroxyl terminus of the growing 
strand is activated, possibly by co-ordination to the enzyme-bound zinc.
(II) The matching deoxynucleotide binds to the enzyme/DNA complex
by co-ordination of the alpha-phosphoryl group to enzyme-bound magnesium 
or manganese.
(III) Formation of a phosphodiester bond and the release of pyrophosphate. 
This marks the end of nucleotide transfer and the beginning of primer 
translocation.
(IV) and (V) Regeneration of a new primer terminus. The enzyme is 
now ready for another nucleotidyl transfer reaction.
•wing 
ind zinc, 
ex
lagne si urn
phosphate.
rimer
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events are controlled.
1.3 Inhibitors of Eukaryotic DNA Synthesis
In prokaryotes mutants have been successfully used in the 
unravelling of complex biochemical events. In eukaryotes this approach 
has met with little success. Instead the use of inhibitors has 
permitted the analysis of many biochemical reactions. Several 
inhibitors of DNA synthesis have now been discovered. The inhibitors 
can be classified according to their mode of action: (a) agents which 
bind to the enzyme, (b) template-modifying chemicals, (c) template 
analogs, (d) substrate analogs, and (e) a variety of chemicals whose 
mechanism of action is still unknown.
1.3.1 Chemical agents binding to the enzyme
1.3.1.1. Thiol blocking agents.
Thiol blocking agents inhibit those DNA polymerases which require 
SH groups for activity. The most commonly used are p-chloromercuri- 
benzoate (PCMB) and N-ethylmaleimide (NEM). The extent of inhibition 
by NEM and PCMB has been used to distinguish the different cellular 
DNA polymerases. DNA polymerase alpha from calf thymus (20), HeLa 
cells (21) and human lymphocytes (22) are completely inhibited by 
concentrations of PCMB and NEM at which DNA polymerase beta from the 
same tissue is relatively resistant. DNA polymerase from rat liver 
mitochondria is not inhibited by PCMB (23). All RNA-dependent DNA 
polymerases from RNA tumor viruses are inhibited by thiol blocking 
agents (24).
As the alpha DNA polymerases are inhibited by 1 mM NEM and the 
beta DNA polymerases are not affected by 10 mM NEM this difference in 
extent of inhibition has been used to distinguish between the two 
types of enzyme. Some care is required, however, in differentiating
alpha and beta DNA polymerases by this method. DNA polymerases have 
been isolated which behave like DNA polymerase beta except that they 
are sensitive to NEM (25).
The requirement for SH groups may be a clue to the mechanism of 
catalysis by DNA polymerases and may be of help in identifying the amino 
acids at the catalytic site. Further it may be possible to use thiol 
inhibitors to distinguish between the enzymes involved in replication 
and those involved in repair. In eukaryotes, as in prokaryotes, it 
appears that repair type DNA synthesis is not inhibited by thiol 
blocking agents (25).
1.3.1.2. Rifamycin derivatives
In general these polycyclic compounds inhibit normal DNA dependent' 
DNA polymerases and viral reverse transcriptases to similar degrees (26). 
Leukaemia DNA polymerase beta has been reported to be inhibited to a 
greater extent than normal lymphocyte DNA polymerase beta (27) . The 
low selectivity of rifamycin derivatives in inhibiting nucleic acid 
polymerising enzymes makes them of little value as specific agents.
1.3.1.3. Pyridoxal phosphate
Pyridoxal phosphate inhibits DNA polymerising enzymes from a 
wide variety of sources (28). This probably indicates that these 
enzymes accept and polymerise deoxyribonucleoside triphosphates by a 
conmon mechanism. Both the aldehyde and phosphate groups are required 
for inhibitory action. Salvo and co-workers (29) demonstrated that 
both lysine and arginine were at the catalytic site of E. coli DNA 
polymerase. This together with the fact that pyridoxal phosphate can 
form Schiff bases with lysine or arginine indicates that lysine and/or 
arginine is involved in the inhibitory action of pyridoxal phosphate.
The phosphate moiety may be required for proper orientation of the 
inhibitor with respect to the substrate binding site before Schiff
15
Figure 1.5
Formation of a Schiff base from pyridoxal phosphate and an amino acid
When pyridoxal phosphate reacts with an amino acid such as arginine 
or lysine an imine or Schiff base is formed. This results from the 
reaction of the aldehyde function of pyridoxal phosphate with the 
side-chain amino group of lysine or arginine.
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base formation between the amino acid residues and the aldehyde group 
of the inhibitor.
1.3.2 Substrate Analogs
Several deoxynucleotide triphosphate analogs have been shown to 
compete with normal substrates and to be incorporated into DNA in vitro. 
Others competitively bind to the active site of the enzymes of DNA 
synthesis or prevent the synthesis of nucleotide precursors.
Many purines and pyrimidines inhibit nucleic acid biosynthesis 
after conversion to the corresponding nucleoside-5'-phosphates (30).
In addition to the polymerases various enzymes which use the normal 
nucleotide may be inhibited. 6-mercaptopurine, for example, is 
converted to 6-thioinosinic acid which inhibits enzymes that effect 
the interconversion of purine nucleotides. 5-fluorouracil, after 
conversion to fluoro-2'-deoxyuridylate, inhibits thymidylate synthetase. 
6-azauridine, formed from 6-azauracil, inhibits the decarboxylation 
of orotidylic acid. This important reaction in the de novo synthesis 
of pyrimidine nucleotides is also inhibited by 5-hydroxyuridylic acid, 
a metabolic product of 5-hydroxyuridine. 9-beta-D-arabinofuranosy1- 
adenine after conversion to the triphosphate inhibits DNA polymerases. 
The inhibition of DNA synthesis by cytosine arabinoside is discussed 
in detail in a later chapter.
Some inhibitors may follow the entire reaction sequence of the 
normal metabolite and become finally incorporated into DNA. Abnormal 
nucleotides in DNA may cause genetic mutation, inhibit further growth 
of DNA chains or result in erroneous transcription. Cell death may 
result in all cases. The halogen derivatives of uracil and uridine 
5-bromouracil, 5-bromo-2'-deoxyuridine, 5-iododeoxyuridine and 
5'-trifluorouridine are incorporated into DNA instead of thymidine 
and interfere with cell replication.
1.3.3. Template Analogs
Single stranded homopolymers without primers have been reported 
to inhibit leukaemia virus DNA polymerases (31). Single stranded 
polyribonucleotides are bound but not used as templates by the 
polymerases. Early reports suggested that inhibition by single 
stranded polyribonucleotides might be used to distinguish the reverse 
transcriptases of RNA tumor viruses from cellular DNA polymerases. 
However, it has been shown that some cellular DNA polymerases are 
inhibited to the same extent as viral enzymes (32).
1.3.4. Template-modifying Agents 
1.3.4.1. Intercalating Agents
A variety of agents act as inhibitors by binding to the template- 
primer. This group includes many antibiotics (actinomycin D, 
ethidium bromide, distamycin, neomycin, and acridine dyes, anthra- 
cyclines, kanchanomycins and 8-aminoquinolines). Many of these 
intercalate into the DNA double helix and do not interact covalently 
with DNA. Some of these may be transformed within the cell to 
produce an active agent which binds to DNA.
Intercalating drugs affect DNA polymerisation by increasing the 
energy required to separate the two strands. Nucleic acids which are 
complexed with acridines are less sensitive to the action of nucleases 
than in the free state. Intercalating dyes inhibit DNA repair by 
disturbing the activity of both DNA polymerases and deoxyribonucleases.
The acridines, of which proflavine is one of the simplest 
members, are planar molecules with three conjugated rings. These 
molecules intercalate with nucleic acids. The intercalation process 
requires planarity and certain size of the ligand and a base paired 
helical secondary structure of the nucleic acid. Proflavine shows 
two modes of binding (33). In addition to the strong intercalation
which occurs at low drug concentrations there is a weaker binding which 
is presumed to be to the outside of the helix.
In vitro proflavine inhibits DNA dependent DNA polymerase. The 
inhibition is due to the acridine binding to the DNA primer. Inhibition 
produced by a given concentration of drug depends on the amount of 
DNA primer present in the incubation mixture (34).
Actinomycin D inhibits RNA synthesis at low concentration and 
DNA synthesis at higher concentrations. Actinomycin D at concentrations 
which inhibit RNA polymerase does not affect the binding of this 
enzyme to the DNA template (35). As in the case of acridines the 
action of actinomycin D can be related to the stabilizing effect it 
has on the double helical structure of DNA. Deoxyguanosine residues 
are essential for the formation of actinomycin D-DNA complexes (36).
Ethidium bromide appears to selectively inhibit mitochondrial 
DNA synthesis in eukaryotic cells (37). It is possible that this 
inhibition of DNA synthesis is due to the inhibition of mitochondrial 
DNA polymerase. Isolated rat liver mitochondrial DNA polymerase has 
been shown to be inhibited by ethidium bromide under conditions in 
which the nuclear enzyme is resistant to the drug (38).
Intercalation is involved in the mechanism of action of the anti- 
malarial drugs chloroquine and quinacrine and anthracycline antibiotics. 
Chloroquine and quinacrine inhibit the in vitro activity of DNA 
polymerases.
1.3.4.2. Alkylating Agents
Alkylating agents generally act by replacing a hydrogen atom in 
a molecule by an alkyl group (39). Frequently alkylation is effected 
by the addition of an alkyl radical to a negatively charged species. 
Molecules that are reactive to alkylating agents contain nucleophilic 
centres involving oxygen, nitrogen and sulphur. At physiological pH
Figure 1.6
Crosslinking between guanine residues on different chains of DNA
In solution the drug forms a reactive cyclic intermediate which 
reacts with the 7 nitrogen of a guanine residue in DNA to form a 
covalent bond. The second arm can then cyclize and react with 
nucleophilic groups such as a second guanine residue in an opposite 
DNA strand or in the same strand. Reactions between DNA and RNA 
and DNA and protein can also occur.
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Figure 1.7
Depurination of DNA after alkylation
In a DNA containing N7-alkylated guanine an equilibrium is set up 
between this quaternary compound (A) and one with the positive charge 
on the Ng (B). These compounds are unstable and alkylated guanine 
(D) is released by cleavage of the bond at G. The remaining part (C) 
rearranges and produces a depurinated patch in the DNA strand (E).
DNA molecules from which guanine bases have been removed are less 
stable than normal DNA. They tend to break down in the area of purine 
deletion by hydrolysis of the phosphate bond.
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the range of groups susceptible to alkylation includes the amino and 
carboxyl groups of amino acids and proteins, the thiol groups of 
cysteine and cysteine residues of protein, imino groups of histidine, 
the primary and secondary hydroxyl groups in nucleotides, the nitrogen 
atoms in purines and the 06 atom in guanine. In general cytotoxic 
alkylating agents and tumor inhibitors are at least bifunctional.
There are several regions in a nucleic acid molecule which can 
be attacked by alkylating agents. An important product of alkylation 
is N^-alkylated guanine. Minor products include N-alkylated adenine 
(N^-adenine) and cytosine. O^-alkylation of guanine also occurs and 
may be involved in the mutagenicity of certain alkylating agents.
The alkylation of guanine in position 7 results in the loss of 
the base from the main DNA chain as shown on the opposite page. The 
DNA molecules from which guanine residues have been removed are less 
stable than normal DNA and break down in the depurinated region by 
hydrolysis of the phosphate bond.
Bifunctional alkylating agents act by cross linking adjacent 
nucleophilic centres. The cross-linked residues may be on the same 
chain or on different ones. If DNA treated with bifunctional 
alkylating agents is acid hydrolysed diguanyl derivatives of the type 
shown on the opposite page are found to be most abundant in the 
hydrolysate. The mechanism by which a nitrogen mustard becomes 
covalently bonded to the 7-nitrogens of two guanines is shown on the 
facing page.
Under neutral or alkaline conditions one of the chloroethyl side 
chains undergoes cyclisation, releasing chloride ion and forming a 
highly reactive immonium ion intermediate. Cleavage of the strained 
ring yields a carbonium ion which reacts with water or with nucleo­
philic groups like amino, carboxyl, phosphate or sulphydryl groups
of proteins and nucleic acids. Depurination in adjacent regions of 
DNA leads to unstable sections on both strands. This would probably 
lead to strand cleavage.
Although the scheme described above is the generally accepted 
view on the mechanism of action of alkylating agents it is not 
possible, at present, to state unequivocally that DNA is the only 
target of importance for these chemicals. Other mechanisms have been 
suggested for the mechanism of action of individual drugs (40).
1.3.5. Other Inhibitors of DNA Synthesis
1.3.5.1. Zinc Chelators
In DNA polymerases from a few sources it has been shown that 
enzyme-bound zinc is necessary for activity. This together with the 
observation that chelating agents inhibit DNA has led to the belief 
that all DNA polymerases are zinc metalloenzymes (18).
The presence of zinc in eukaryotic DNA polymerases has not been 
reported. None of the enzymes show a requirement for added zinc for 
catalytic activity. This may be due to the presence of tightly bound 
zinc associated with the polymerase molecule. The presence of zinc 
in many eukaryotic DNA polymerases is implied by inhibition studies 
which use chelators such as o-phenanthroline which have great affinity 
for zinc. The observed inhibition cannot be due to the interaction 
of o-phenanthroline with magnesium as this ion is added in excess. 
Although o-phenanthroline has a high affinity for zinc it also binds 
to other ions like copper and iron.
1.3.5.2. Metal Ions
All known DNA polymerases require an added divalent metal ion 
for activity. Several divalent cations can substitute for magnesium 
or manganese during catalysis (39). With activated calf thymus DNA 
as template-primer, sea urchin nuclear DNA polymerase can effectively
use cobalt, nickel, manganese or zinc in place of magnesium. Substi­
tution of barium, calcium or strontium for magnesium does not lead 
to detectable incorporation of deoxyribonucleotides.
Some monovalent and divalent metal ions can inhibit DNA synthesis. 
Although information is available about the inhibition of prokaryotic 
DNA polymerases (7) little is known about the inhibition of mammalian 
DNA polymerases by metal ions. Bollum (20) has described the 
inhibition of DNA polymerase alpha by potassium, sodium, lithium, and 
ammonium chlorides. Inhibition of DNA polymerases from human KB cells 
(41), HeLa cells (42), rabbit (43) and mouse testis (44) by sodium 
and potassium has been studied.
1.3.5.3. Agents with unknown modes of action
Nitrosoureas inhibit DNA synthesis in cultured cells and in cell- 
free extracts. The mechanism of action is unclear but may involve 
alkylation of the DNA template or the formation or carbamyl derivatives 
of the enzyme. A number of nitrosourea derivatives have been shown 
to be specific inhibitors of purified DNA polymerase alpha from rat 
liver and hepatomas (45). Pre-incubation of the enzyme with nitro­
soureas increases the extent of inhibition. Isocyanates, breakdown 
products of nitrosoureas inhibit DNA polymerase alpha to a greater 
extent than the parent compounds.
Bleomycin, a glycopeptide antibiotic inhibits bacterial and 
mammalian cell growth and has antitumor activity. It inhibits DNA 
synthesis by viral reverse transcriptase, DNA polymerases alpha and 
beta (46) but DNA polymerase gamma and terminal deoxynucléotidyl 
transferase are unaffected.
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1.4 Enzymes of DNA Synthesis
1.4.1 Eukaryotic DNA Polymerases
UNA polymerases catalyze the formation of a phosphodiester bond 
between the 5'-phosphate group of the incoming deoxyribonucleotide and 
the 3'-hydroxyl end of the primer. It is now accepted that DNA from 
a variety of eukaryotic cells existsin multiple forms. The multiplicity 
of DNA polymerases raises the question of the biological function of 
these enzymes. Four main eukaryotic DNA polymerases can be distinguished 
(47, 48, 49, 50, 51, 52, 53, 54). A comnon nomenclature has been 
devised for these enzymes (55).
There is general agreement that the high molecular weight (6-8S)
DNA polymerase, usually obtained from the cytoplasmic fraction of cells 
is DNA polymerase alpha. The low molecular weight enzyme (3-4.5S) 
usually isolated from nuclei is designated DNA polymerase beta. A 
third polymerase, DNA polymerase gamma found in both cytoplasm and 
nuclei shows preference for replicating oligonucleotide-primed 
homopolymeric ribonucleotides such as (dT)^(A)n> A fourth DNA 
polymerase activity has been found associated with the mitochondria of 
several mammalian cells (56).
All eukaryotic DNA polymerase use activated DNA as a template- 
primer. Unlike bacterial DNA polymerases they lack associated nuclease 
activity. The enzymes differ in size, structure, template-primer 
specificity and in the requirement of thiol groups for activity.
1.4.1.1. DNA Polymerase alpha
DNA polymerase alpha was the first eukaryotic DNA polymerase to 
be identified (57). It has been prepared from calf thymus (57), HeLa 
cells (58), rat tissues (59), human KB cells (60), avian cells (61), 
baby hamster kidney cells (62) and mouse L cells (63).
The sedimentation properties of the purified enzyme are strongly
influenced by the ionic strength. In the absence of sodium chloride 
DNA polymerase alpha from mouse L cells and calf thymus sediments at 
7S. This corresponds to a molecular weight of 130 000. In the 
presence of 0.5M sodium chloride, however, the enzyme sediments at 5S, 
corresponding to a molecular weight of 70 000.
DNA polymerase alpha is the predominant DNA polymerase activity 
of growing cells where it often represents 80 - 90% of the total cell 
DNA polymerase content. As with all known DNA polymerases, DNA 
polymerase alpha requires 3'-0H priming groups as initiators. It 
copies gapped duplex DNA (activated DNA prepared by the action of 
DNAse I on duplex DNA) at a high rate. DNA polymerase alpha can use 
synthetic DNA homopolymer templates well with both DNA and RNA primers. 
It is unable to copy RNA templates. Reactions with synthetic template- 
primers proceed best with Mn as the divalent cation but those with 
natural DNA templates proceed best with Mg.
The de novo synthesis, in vitro, of polyd(A-T) by calf thymus 
DNA polymerase alpha has been reported (64). This synthesis, which 
occurs after a long lag period, occurs both with and without the 
addition of DNA and unwinding protein. The synthesis of polyd(A-T) was 
shown to be autocatalytic and exponential. Earlier the same group 
had reported the replication of single-stranded DNA by DNA polymerase 
alpha. The product was shown to be double-stranded DNA with a hairpin 
structure.
Calf thymus DNA polymerase alpha can carry out pyrophosphate 
exchange and pyrophosphorolysis reactions but no associated nuclease 
activity has been demonstrated (12). The pH optimum of the enzyme 
ranges from 7-8 depending on the buffer used. It is particularly 
sensitive to high ionic strength. DNA polymerase alpha is sensitive 
to NEM (8), high concentration of actinomycin D, and AraCTP (65).
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Although most easily detected in the cytoplasm, DNA polymerase 
alpha has also been found in the nucleus. The sensitivity of the 
enzyme to promotors of cell proliferation and to inhibitors of mitosis 
and replication shows that the enzyme may be important in replicating 
DNA under physiological conditions.
DNA polymerase alpha is generally considered to be the true DNA 
replicative enzyme. Further work on this enzyme has been hampered by 
the difficulty encountered in its purification. It has not been 
possible to purify the enzyme to homogeneity. Heterogeneity may 
reflect proteolytic degradation of the enzyme during purification to 
yield smaller molecules which retain polymerase activity. On the 
other hand it is possible that the heterogeneity of the enzyme is a 
reflection of its biological role. The fluctuation which occurs in 
its activity during the growth of a cell are correlated with rate of 
DNA replication and may also be associated with molecular weight changes.
Although there is general agreement that DNA polymerase alpha 
probably consists of subunits, the number, size and structural relation­
ship of these units is yet to be worked out (52).
In view of the observation that DNA synthesis in both prokaryotes 
and eukaryotes begins by the coupling of a deoxyribonucleotide to the 
3'-OH group of RNA, the ability of polymerase alpha to use RNA primers 
is significant. Although other DNA polymerases can use RNA primers 
with synthetic DNA templates, only DNA polymerase alpha can synthesize 
DNA covalently bonded to natural RNA primers (6 6). This would 
indicate that the enzyme can initiate DNA synthesis in vivo and would 
make it a strong candidate as the replicative enzyme.
1.4.1.2. DNA Polymerase beta
The low molecular weight DNA polymerase beta comprises 5-15% of 
the total DNA polymerase of dividing cells but up to 50% of the
activity in non-dividing cells. Although the enzyme is usually 
found in the nucleus it is also reported to be present in the cyto­
plasm (67). The enzyme has been isolated from HeLa cells (57), rat 
liver (6 8) and PHA-stimulated human lymphocytes (69) . Because of its 
size, location, charge, and relative abundance in non-proliferating 
tissue this DNA polymerase has been the easiest to purify. In calf 
thymus (70) and human KB cells (71) the enzyme has been purified to 
homogeneity.
DNA polymerase beta from calf thymus and human KB cells is a 
single polypeptide chain with a molecular weight of 43 000 - 45 000.
The molecular weight of the enzyme isolated from other sources ranges 
from 35 000 - 45 000 (70). Although sodium dodecyl sulfate (SDS) 
polyacrylamide gel electrophoresis shows no evidence of subunit 
structure under certain conditions of low ionic strength the enzyme 
forms aggregates with a molecular weight of 250 000 (71). In mouse 
cells the aggregated low molecular weight enzyme has sometimes been 
mistaken for DNA polymerase alpha (72).
With activated DNA as template-primer, DNA polymerase alpha 
requires all the four deoxynucleotides for maximal activity. However, 
some incorporation with only one, two or three of the deoxyribonucleo- 
tide substrates and activated template has been reported (73). DNA 
polymerase beta may, therefore, have been confused with terminal 
deoxynucléotidyl transferase, an enzyme which catalyses the polymer­
ization of deoxynucleotides on the 3'-hydroxy ends of oligo and poly- 
deoxyribonucleotides in the absence of template. The purified enzyme, 
however, does not show terminal deoxynucléotidyl transferase activity 
when assayed under conditions which are optimal for transferase activity.
Purified DNA polymerase beta has no associated nuclease activity 
nor does it carry out pyrophosphate exchange (60). The enzyme functions
optimally at alkaline pH and has an alkaline isoelectric point. The 
DNA polymerase beta purified from calf thymus chromatin is a basic 
protein. Although DNA polymerase beta is inhibited by p-chloromercuri- 
benzoate it is less sensitive to NEM than DNA polymerase alpha (48).
The enzyme is not inhibited by 20% ethanol or 25% acetone and is 
stable in 5M urea (74).
Mosbaugh and others (75) have reported the association of highly 
purified DNA polymerase beta from Novikoff hepatoma cells with 
another protein, Novikoff factor IV. This protein stimulates the 
enzyme fourfold and converts the 3.3S polymerase to the 4.IS form.
Other proteins could be involved in the conversion to the observed
5.8 and 7.3S forms.
1.4.1.3. DNA Polymerase gamma
The separation of DNA polymerase gamma and its differentiation 
from alpha and beta DNA polymerases in HeLa cells was first described 
by Fridlender and co-workers (76). The enzyme has been reported in 
a variety of sources including human lymphocytes, HeLa cells, rat 
liver and chick embryo (77).
DNA polymerase gamma requires thiol groups for activity. It can 
use either magnesium or manganese as the metal ion. In HeLa cells the 
enzyme shows values for deoxynucleotides that are an order of 
magnitude lower than the K^ , values for DNA polymerase alpha and beta.
It has been suggested that ganma DNA polymerase may use deoxynucleotide 
triphosphates during the S phase when the deoxynucleotide pool is 
relatively low (51).
DNA polymerase gamma has a pH optimum of between 7 and 8 . It 
prefers manganese when copying its preferred template (dT)i5 (A)n.
The unique property of DNA polymerase gamma is its ability to copy 
synthetic ribohomopolymers such as (dT)1 5 (A)n at a higher rate than
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deoxyribohomopolymer templates such as (dT)^5 (dA)n or activated DNA. 
Unlike reverse transcriptases, DNA polymerase gamma does not use 
poly (C)dG^5 or natural RNA to an appreciable extent (78).
In HeLa cells DNA polymerase gamma is found in both the cyto­
plasmic and the nuclear fractions. The cytoplasmic enzyme can be 
separated into two forms on hydroxyapatite columns. The two forms, 
both of molecular weight 1 0 0 0 0 0 daltons, differ in their ability to 
copy ribohomopolymers such as poly(I), poly(C), or poly(U) (79).
Form I copies poly(A) templates well but copies poly(C) , poly(I) 
and poly(U) very poorly. Form II can copy all of the homopolymers 
well. The two forms also show different inhibition patterns in the 
presence of salt or ethanol (80).
N-ethylmaleimide (1 mM) inhibits nearly half the activity of DNA 
polymerase gamma but p-chloromercuribenzoate (1 mM) inhibits the 
activity completely. The purified enzyme has been reported to be 
unable to catalyse pyrophosphate exchange (81).
DNA polymerase gamma comprises only one percent of the total 
cell DNA polymerase activity. Its function may, therefore, be a 
specialised one. On the other hand it is possible that the enzyme 
occurs in high concentration in certain cells or during certain 
phases of development.
1.4.1.4. Mitochondrial DNA polymerase
Mitochondrial DNA polymerase, another minor polymerase which is 
found in mitochondria, is active in high salt and can copy mitochondrial 
DNA (82). Some workers have reported differences between mitochondrial 
and gamma DNA polymerases from the same source in their sensitivity 
to inhibitors and their efficiency in using template-primers (83). In 
contrast others do not find any differences in the sedimentation or 
catalytic properties of these enzymes (84). The responses of these
4><. * - 1 «a rt
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enzymes as to inhibitors was found to be identical.
It has not been easy to demonstrate that mitochondrial DNA 
polymerase is indeed associated with that organelle. In any case 
mitochondrial DNA polymerase comprises only a small percentage of the 
total cell DNA polymerase activity. While it would be important for 
mitochondrial function it is not expected to play a critical role in 
the biology of the cell as a whole. If mitochondrial DNA polymerase 
and DNA polymerase gamma are indeed one enzyme, then the presence of 
this enzyme in the cytoplasm is baffling.
1.4.1.5. Terminal deoxynucleotidy1 Transferase
Terminal deoxyribonucleotidy1 transferase is not a normal DNA 
polymerase in that it does not require a template to direct DNA 
synthesis. Although low levels of the enzyme have been reported in 
bone marrow (85) it is almost exclusively found in the thymus (8 6).
The enzyme has a molecular weight of about 32 000 and comprises 
two subunits of 8 000 and 26 000 daltons. Two forms of terminal 
deoxyribonucleotidyl transferase have been described. Both have the 
same molecular weight and primer and substrate preferences (87). They 
differ in their response to cortisone treatment. Form I is more 
resistant than form II. Also whereas the levels of form I terminal 
transferase are similar for all ages and strains of mice the levels 
of form II vary with both strain and age (52).
Cell lines derived from cells of patients with acute lymphoblastic 
leukaemia have high levels of terminal deoxynucleotidy1 transferase.
The enzyme could, therefore, be used as a biochemical marker for 
certain types of leukaemia. Although terminal transferase from 
leukaemia cells has properties similar to the calf thymus enzyme 
differences have been reported. The enzymes show different divalent 
cation preferences when polymerising dG with (dA)^ as initiator (8 8).
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1.4.1.6. Location of DNA Polymerase in Cells
Except for mitochondrial DNA polymerase and polymerases of viral 
origin, DNA polymerases would be expected to occur in the nucleus 
where DNA synthesis takes place. It was surprising to find that, using 
standard procedures of enzyme fractionation, a fraction of the total 
polymerase activity was always recovered in the cytoplasmic fraction. 
The presence of DNA polymerase in the cytoplasmic fraction could be 
an artifact of the fractionation procedure (48).
The finding that when nonqueous media are used most of the cell 
polymerase activity is recovered from the nucleus (69) , led to the 
conclusion that both DNA polymerase alpha and beta are nuclear. This 
conclusion has been challenged (89) and the question whether DNA 
polymerase alpha is a nuclear enzyme or not is still unresolved.
Although it has been suggested that DNA replication occurs at 
the cell membrane there is no agreement as to whether this is the 
case or whether any of the enzymes of DNA synthesis are located there.
1.4.2. Other Enzymes of DNA Synthesis
Although DNA polymerases have been the most thoroughly studied 
of the enzymes involved in DNA replication it is becoming clear that 
the process of DNA synthesis requires the interaction of several 
proteins. The action of most of these proteins is poorly understood. 
The presence of some of these enzymes is predicted from the proposed 
mechanism of DNA synthesis whose general outline is now widely 
accepted.
1.4.2.1. Ligases
The mechanism of DNA synthesis discussed earlier on in the 
chapter involves the formation of short pieces of DNA which are joined 
together in the later stages of chromosome replication. DNA ligases 
catalyze the formation of phosphodiester bonds between adjacent 5'-
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phosphoryl and 3'-hydroxyl ends in double-stranded DNA. These enzymes 
are required both for the replication and repair of DNA. In vivo 
ligases probably act in concert with the DNA polymerases.
DNA ligases have been detected, isolated and characterised from 
several vertebrate species (90). Whereas bacteria have only one DNA 
ligase mammalian cells contain at least two ligases (91). DNA ligase I, 
the larger and more abundant of these enzymes, can occur in both a 
dimeric and monomeric form.
The mechanism of reaction of mammalian ligases is similar to that 
of the DNA ligase in E.coli (92). In the presence of cofactor the 
enzyme forms a complex with AMP. The adenylate moiety of the complex 
is then discharged in a reaction that required magnesium ions.
Although DNA ligases have not received as much attention as the 
polymerases these enzymes are likely to play a key role in DNA 
synthesis.
1.4.2.2. Helix-destabilising Proteins
Proteins which bind to single-stranded DNA in preference to 
double-helical DNA have been isolated from mammalian systems (93).
These proteins markedly depress the helix-melting temperature of DNA. 
Unwinding protein from calf thymus (94) was found to stimulate DNA 
polymerase alpha. It was suggested that unwinding proteins caused 
this stimulation by inhibition of the formation of hairpin helices.
The biological role of unwinding protein is still unclear.
1.4.3. DNA Polymerases of the Lower Eukaryotes
Unlike the genetic approach used with bacterial systems, it has 
not generally been possible to use mutants in investigating various 
aspects of eukaryotic DNA synthesis. However, with the haploid stage 
of the smut fungus Ustilago maydis it has been possible to develop a
mutant, Pol 1, deficient in DNA replication (95). This mutant was
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temperature sensitive for both cell growth and DNA synthesis. Pol-1 
contained only 10-25% of the wild type DNA polymerase activity when 
cells are incubated at the restrictive temperature of 32°C. When DNA 
polymerase was purified from the strain Pol-1 grown at the permissive 
temperature of 22°C, the enzyme was found to be heat-labile.
The wild type enzyme was found to have a molecular weight of 180 - 
200 000. The DNA polymerase operated optimally at pH 7.5 and 120 mM 
KC1. The activity was inhibited by N-ethylmaleimide and ethanol. A 
3 ' to 5 ' exonuclease activity was always associated with the polymerase 
activity. The major Ustilago maydis DNA polymerase was inhibited by 
the zinc complexing agent o-phenanthroline. This was taken to mean that 
zinc was probably a component of the enzyme (96).
In addition to mitochondrial DNA polymerase two DNA polymeraseg,
A and B have been characterized from Euglena (97). Both enzymes have 
an optimum pH of 7.2,"and function best in 25 mM potassium and 2 mM 
magnesium. Both enzymes preferred manganese to magnesium and were 
inhibited by NEM.
The enzymes differed in that only the B form was able to use an 
oligo(dT)-initiated poly(A) template and possessed exonuclease activity 
which could hydrolyse single-stranded DNA and the RNA of the DNA.RNA 
hybrid.
A multiplicity of DNA polymerases has been observed in Paramecium 
(98), Chlamydomonas (99) and yeast (100). The DNA polymerases of 
Paramecium are similar to those of Euglena. Yeast contained two forms 
of DNA polymerases. Yeast enzyme I was found to resemble DNA polymerase 
alpha but yeast enzyme II was similar to prokaryotic DNA polymerase 
II and III. The two enzymes could be separated by chromatography on 
DEAE-cellulose, hydroxyapatite or DNA-cellulose (101). Both enzymes 
had a molecular weight of about 100 000. Enzyme I had no associated
nuclease activity but carried out pyrophosphate exchange and pyro- 
phosphorolysis reactions. Enzyme II carried out pyrophosphate 
exchange and phosphorolysis and had an associated exonuclease activity. 
Whereas enzyme I could not use mismatched templates, enzyme II could 
excise mismatched 3'- nucleotides from suitable templates. Both 
enzymes were sensitive to NEM.
Only one DNA polymerase has been described in some primitive 
eukaryotes like Tetrahymena (102), Dictyostelium discoideum (103) and 
Chlorella (104). DNA polymerase from Tetrahymena pyriformis was 
found to have a molecular weight of 80 000. In solutions of low 
ionic strength the enzyme formed aggregates. With manganese as the 
metal ion the enzyme was able to copy RNA templates and extend 
oligodeoxynucleotide primers. Throughout all the stages of purification 
the enzyme contained associated DNAse activity. In this thesis, I 
report evidence for the multiplicity of the DNA polymerase activity 
of Tetrahymena.
The enzyme from Dictyostelium was found in all stages of growth 
and development including spores. Unlike DNA polymerase alpha of the 
higher eukaryotes the level of the polymerase in Dictyostelium did 
not vary widely with the rate of cell growth. The enzyme was completely 
inactivated by NEM.
The absence of an enzyme with any resemblance to DNA polymerase 
beta from the primitive eukaryotes probably indicates that this enzyme 
evolved later than DNA polymerase alpha. It has been suggested that 
this more recent appearance was possibly to meet some unique function 
in the more complex eukaryotes (103). This new function might be a 
special type of DNA replication - possibly repair. Until the roles of 
the different eukaryotic polymerases are properly worked out these 
ideas will remain conjectural.
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1,4.4. Control of DNA Synthesis
The factors which control the initiation, maintenance and 
termination of DNA synthesis are still poorly understood. DNA 
replication and histone synthesis are closely coupled and are probably 
influenced by the same control mechanisms.
A possible clue to the control of DNA initiation is the observa­
tion that the number of active origins for DNA synthesis depends on 
the physiological state of the cell (1). There may be different 
initiator proteins which interact with different sets of origins 
which are defined by specific base sequences. Another possibility is 
that a single set of initiator proteins interacts with varying affinity 
with different sets of origins. It is also possible that origins are 
defined by the secondary structure of DNA and not simply by nucleotide 
sequence.
Many hormones, mitogens and mitotic inhibitors that control cell 
proliferation act by regulating the progression of cells from the Gj 
to the S phase of the cell cycle and are presumed to affect the 
initiation of DNA synthesis. The effect of these substances on DNA 
synthesis is not direct (105). Many agents which cause cells to 
progress from G^ to S first lead to increased RNA (rRNA) synthesis 
and chemical modification (acetylation and phosphorylation) of chromo­
somal proteins. These events occur before the initiation of DNA 
synthesis.
Work with various cell types shows that a given cell type traverses 
the S, G2 , and M phases at a constant time during every cycle. In 
contrast the length of the Cl phase varies between individuals in the 
same population of cells. The current view is that the G^ phase is 
comprised of a fixed part, B, and a variable one, the G0 or A part (106). 
It is the variability of the G0 phase which is responsible for the
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Figure 1.9
Circular and linear diagrams of the eukaryotic cell cycle
All cells pass through a sequence of stages which are referred to as 
the cell cycle. Immediately after mitosis (M) daughter cells enter 
the Gi phase. Some differentiated cells, such as the enucleated 
erythrocytes of frogs and birds and the neurones of all tetrapods, 
remain permanently in the Gj phase. In tissues whose cells divide 
the Gj phase is followed by the S period during which DNA synthesis 
occurs. After DNA synthesis a G2 period may intervene prior to 
mitosis and cell division. The length of the G^ and G2 periods vary 
markedly between species. In some cell lines the G^ phase is 
virtually absent. For a particular strain of cells the G2 and M 
periods appear to be constant. The approximate durations for each 
phase of the cycle are one hour for the M phase, 1 - 8  hours for the 
Gi phase, 6 - 8  hours for the S phase and 2 - 4  hours for the G2 
phase. Some cells continuously move around the cycle but others 
leave the cycle temporarily to enter the Gq period. Cells in the Gq 
phase can be induced to synthesize DNA and divide again. Some cells 
leave the cell cycle definitely and become destined to die without 
dividing again.
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Figure 1.9. Diagram of the eukaryotic cell cycle
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variability of the G^ phase and for asynchrony of cell division in 
cell populations. It is not yet known whether the G0 phase is in the 
early or late part of the Gj phase. Details about the events which 
trigger the transition from A to B also remain unknown.
There is evidence that the cell's ability to initiate DNA 
synthesis is under positive control. In vitro studies with nuclei 
isolated from cells at different stages of the cell cycle show that 
differences in the rate of DNA synthesis between active and inactive 
cells are retained in nuclei isolated from these cells (107, 108).
Nuclei from cells synthesising DNA rapidly incorporate precursors 
into DNA more rapidly than nuclei from inactive cells. Attempts to 
isolate protein factors which stimulate Gi nuclei to synthesise DNA 
have not produced conclusive proof of the existence of these proteins 
(109).
2. Aims of the Project
In this project Tetrahymena pyriformis was used as the experimental 
organism. There are a number of advantages in working with this 
organism. Tetrahymena was the first protozoan to have its growth 
requirements fully characterized (110). Its nutritional requirements 
are similar to those of higher eukaryotes and the cells can be induced 
to grow in a synchronous fashion by a variety of simple techniques (1 1 1 ). 
The short generation time of about three hours and the asexual mode 
of replication of the amicronucleate strain used made Tetrahymena 
a convenient organism to work with.
Because of their central role in DNA cell replication, DNA 
polymerases are currently being studied as possible target enzymes in 
cancer chemotherapy. At present it seems that there are at least two 
DNA polymerases in the nuclei of higher eukaryotes (52, 53). The 
first, DNA polymerase alpha, is thought to be involved in DNA
replication. The second, DNA polymerase beta, is thought to be a DNA 
repair enzyme. No enzyme with properties similar to those of DNA 
polymerase beta has been detected in the lower eukaryotes (112). A 
primary aim of the project was to determine how many types of DNA 
polymerase could be detected in Tetrahymena and to determine their 
function. A secondary aim was to study the location of DNA polymerases 
in Tetrahymena cells. I hoped to develop a method of preparing 
nuclei which would not allow DNA polymerases to escape into cytoplasmic 
fractions.
A further primary aim of the project was to study the effect of 
AraC and AraCTP on DNA replication in Tetrahymena. Specifically the 
effect of AraC on the formation of intermediates in DNA replication 
was to be investigated. I also wanted to study the effect of AraCTP 
on the DNA polymerases of Tetrahymena. A clear understanding of the 
effect of AraC on DNA synthesis should contribute towards the more 
rational use of this drug in the treatment of cancer.
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CHAPTER 2
2.1 THE EFFECT OF CYTOSINE ARABINOSIDE ON DNA SYNTHESIS
Cytosine arabinoside (AraC), a synthetic pyrimidine nucleoside, 
differs in its sugar moiety from the normal metabolites cytidine and 
deoxycytidine (Figure 2.1). The chemical properties of AraC have been 
reviewed (113) and recently the conformation of arabinosyl nucleosides 
has been studied (114). Soon after its discovery (115, 116) AraC 
was found to have antileukaemic (117) and antiviral properties (118). 
AraC is now one of the most effective drugs used to treat acute myelo­
genous leukaemia and other malignancies. The therapeutic value of AraC 
appears to derive from its ability to inhibit DNA synthesis (113) or 
from synthesis of altered DNA (119) resulting in cell death. It is 
unclear why AraC exhibits nonspecific toxicity to most eukaryotic 
cells but selectively kills fast replicating cancer cells in human 
and experimental animals.
Although AraC has continued to be used for treatment of some 
leukaemias in adults and children remission rates have been low. 
Improvement may be achieved by changing dose schedules to allow 
recovery of normal bone marrow and minimise immunosuppression. Effect­
iveness may also be improved by combination with certain alkylating 
agents and thiopurines.
2.1.1 Toxicity of AraC in Cells
Before AraC was used to treat cancer patients its toxicity in 
rodents, dogs and monkeys was tested (122). The main toxic effect was 
exerted against bone marrow. A similar effect was observed in humans 
(123). Human marrow cells developed marked chromosomal changes.
In bacteria large concentrations of AraC (1 mg/ml) are required 
for lethality (125, 126). Even strains which lack cytidine deaminase
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Figure 2.1
Cytosine arabinoside and related natural nucleosides
Cytosine arabinoside differs from cytidine in the orientation of 
the hydroxyl group on the 2-carbon of the ribofuranose ring. 
Deoxycytidine does not have a hydroxyl group on this carbon.
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are not easily killed by AraC. In contrast to mammalian DNA 
polymerases E. coli DNA polymerase I is insensitive to AraCTP (127, 128).
Kim and Eidinoff found that in HeLa cells there was a lag in the 
lethal effect of AraC (132). They concluded that cells were 
accumulating prior to or at the beginning of the S phase of the cell 
cycle. When the drug was removed most of the cells entered mitosis 
synchronously. The synchronized cell populations were then used to 
study the stage at which cell death occurred in the presence of AraC.
They found that the stage of cell death corresponded closely to the 
S phase. It has been suggested that the effectiveness of AraC in 
killing cells would be improved by using treatment schedules that 
maximize the proportion of cells passing through the S phase.
AraC does not prevent cells in G2 from progressing to mitosis 
(133). The passage of cells from S to G2 is affected to a greater 
extent than passage from G^ to S (134). The greatest inhibition occurs 
during the last half of the S phase. This time corresponds to the 
period of maximal damage under the influence of AraC. It appears that 
the second half of the S phase is the most sensitive for cell kill 
which occurs when there are five or more chromatid breaks per cell. 
Introduction of only one or two breaks does not lead to detectable cell 
death (135).
In human cells AraC is thought to cause chromatid breakage in 
the G|, G2 and mitotic stages (136, 160). In these stages AraC is not 
an effective killing agent. At present the predominant view is that 
AraC kills cells by affecting semi-conservative DNA synthesis occurring 
during the S phase.
In fetal mice and rats AraC is teratogenic. AraC will transform 
hamster and rat cells in culture to the malignant state (138). The
transformations occur more easily with cells treated with the drug in 
the S phase than with Gj arrested cells. The transforming and inhibi­
tory effects of AraC in tissue culture and in intact animals can be 
prevented by deoxycytidine (120, 121, 137).
It appears that AraCTP is the major toxic agent formed from AraC.
A subline of L1210 leukaemia which is resistant to AraC is unable to 
metabolise AraC or deoxycytidine (138). Development and maintenance 
of lethal intracellular concentrations of AraCTP depend on such 
factors as the rate of uptake of AraC, the rate of deamination or 
other degradation, the rate of phosphorylation and the turnover of 
AraCTP. As the external concentration of AraC decreases, the turnover 
of AraCTP in the cell will decrease the intracellular concentration of 
this toxic product and allow survival and multiplication of temporarily 
inhibited cells.
2.1.2. Metabolism of cytosine arabinoside (Figure 2.2)
2.1.2.1. Transport
Nucleosides such as AraC will pass across the cell membrane and 
will accumulate in cells in the form of their 5'- phosphates. 
Deaminated nucleosides do not accumulate but are rapidly excreted (138) 
In L1210 cells, purine and pyrimidine nucleosides inhibit the entrance 
of AraC but only pyrimidines inhibited the rapid exit of AraC (161).
2.1.2.2. Deamination
Early studies showed that under the usual conditions of adminis­
tration to humans and various experimental animals, AraC is rapidly 
converted by cytidine deaminase to AraU. AraU may be excreted as 
such in urine or it may be cleaved to uracil. About 5% of AraC is 
excreted unchanged. In rats which have a low deaminase activity, about 
70Z of the drug was excreted unchanged (162).
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Figure 2 . 2
Diagram showing the metabolism of cytosine arabinoside in cells
After passing across the cell membrane AraC may be converted to 
AraCMP by deoxycytidine kinase. AraC may also be deaminated by 
cytidine deaminase to produce nontoxic AraU. AraCMP is further 
phosphorylated by deoxycytidine monophosphate kinase to yield AraCDP. 
A non-specific nucleoside diphosphokinase then phosphorylates 
AraCDP to produce AraCTP. The current view is that it is the AraCTP, 
an analogue of dCTP, which then interferes with DNA synthesis.
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In HeLa cell cultures, exposure to AraC causes a fourfold 
increase in cytidine deaminase activity even in the presence of the 
inhibitor of protein synthesis, cycloheximide (147). Cytidine 
deaminase may, therefore, be involved in resistance to AraC by certain 
cells ( 148) .
During a systematic search for inhibitors of cytidine deaminase 
a potent inhibitor, tetrahydrouridine (THU) was discovered (149, 124). 
Tetrahydrouridine inhibits human liver cytidine deaminase with a Ki 
of 1.3 x 10- 7  M. At high concentrations (10- )^ THU inhibited AraC 
(150) phosphorylation by a human liver preparation.
2.1.2.3. Phosphorylation
AraC is converted to AraCTP by three successive enzymic reactions 
(163). Initially AraC is converted to AraCMP by deoxycytidine kinase. 
Further phosphorylation by deoxycytidine monophosphate kinase yields 
AraCDP. Finally a nucleoside diphosphokinase converts AraCDP to 
AraCTP. In mice injected with L1210 ascites cells, the tissue level 
of AraCTP appears to determine cellular toxicity and chemotherapeutic 
efficacy of AraC (140). It is probably significant that the leukaemic 
cells of AraC-treated cells have AraCTP concentrations ten times 
higher than normal cells. AraUMP was detected in the monophosphate 
fraction from leukaemic mice (140). This may have been produced from 
the phosphorylation of AraU or the deamination of AraCMP (164).
2.1.3 Resistance of cells to AraC
Leukaemic cells from patients treated with AraC often develop 
resistance to the drug if they survive the first dose of the drug.
There are at least three different hypotheses to explain the appearance 
of resistant cells. The development of resistance to AraC may be 
caused by a decrease in the kinase capable of phosphorylating AraC
(141 142, 143). In some resistant cell lines it was found that
there remained in the mitochondria a kinase capable of phosphorylating 
deoxycytidine but not AraC (165). Some drug resistant cells not only 
lack an AraC kinase but also have increased levels of ribonucleotide 
reductase or an insensitivity of this enzyme to dATP (144). This 
could lead to increased levels of protective dCTP (145). The 
resistance of some cells to AraC could also be associated with their 
ability to deaminate this drug to the nontoxic derivative AraU.
2.1. A The mode of action of AraC
AraC at high concentrations can potentially interfere with many 
different biochemical processes. At low concentrations it inhibits 
DNA synthesis fairly specifically. A number of proposals have been 
put forward to explain the action of AraC in inhibiting DNA synthesis 
and causing cell death. Some of these are discussed below.
2.1.4.1. Inhibition of cytidine reductase
After it was observed that deoxycytidine prevented toxicity by 
AraC it was suggested that AraC or one of its metabolites exerted its 
effect by inhibiting ribonucleotide reductase (120). This enzyme 
converts CDP to dCDP. However, neither AraCDP nor AraCTP are inhibitors 
of mammalian ribonucleotide reductase (151). Also in L cells 
inhibited by AraC, normal levels of dCTP accumulate (152). It, 
therefore, appears that neither AraC nor any of its derivatives cause 
cell toxicity by inhibiting ribonucleotide reductase.
2.1.4.2. Inhibition of DNA polymerases
It lias been suggested that AraC caused cell death by inhibiting 
DNA polymerases and thus inhibiting DNA (153). It is proposed that 
AraC, after conversion to AraCTP,competes with dCTP as a substrate 
for DNA polymerases. AraCTP is a powerful inhibitor of DNA polymerases
in both normal and tumour cells (152, 128, 154). The observation 
that AraC does not interfere with the synthesis of dCTP and dTTP 
from exogenously supplied deoxynucleosides, but inhibits their 
incorporation into DNA (152) is in agreement with the suggestion 
above.
Although AraCTP competitively inhibits dCTP utilization by the 
polymerases it does not inhibit polyd(A-T) synthesis by tumor DNA 
polymerase (155). In general the inhibition of cellular and viral 
DNA polymerases by AraCTP is dependent on the template used. DNA 
polymerase alpha is more sensitive to AraCTP than DNA polymerase 
beta (162, 167).
2.1.4.3. Incorporation into nucleic acids
Finally it is possible that AraC kills cells by being incorporated 
into DNA. If AraCTP is incorporated into DNA chains it could occur 
within polynucleotide chains or only in terminal positions where it 
would block extension of the DNA chains.
Early reports claiming that AraC was incorporated into DNA were 
received with scepticism partly because the separation conditions were 
not always ideal and only small amounts of the applied isotope were 
recovered in DNA (141, 156, 157). The AraC used was of high specific 
activity. Further cytidine deaminase and nucleoside phosphorylase 
could degrade AraC to uracil and cytosine significant amounts of 
which could enter RNA and DNA. The early results have been supported 
by improved chromatography and by the demonstration in vitro that 
AraCTP was incorporated into DNA by DNA polymerases (152, 158, 154).
Studies on mairanalian DNA with AraCTP in the absence of dCTP 
support the hypothesis that AraC is incorporated into terminal 
position in nascent DNA (159). When L cells were treated with AraC
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to kill a high proportion of the cells after centrifugation and 
washing the surviving cells were still capable of incorporating 
thymidine into DNA at normal rates (130). This was taken to mean 
that AraC did not terminate DNA chains. However, other workers 
found that most of the AraC was incorporated into alkali-resistant 
fractions (152, 158).
At present the hypothesis that AraC inhibits DNA synthesis and 
causes cell death by competitive inhibition of DNA polymerases and 
by incorporation onto DNA appears to be the most reasonable.
2.1.5. The effect of cytosine arabinoside on RNA and protein synthesis 
Claims that AraC is incorporated into RNA are unconvincing. The
RNA polymerases studied so far cannot incorporate AraCTP into RNA 
(127, 128). In murine leukaemic cells (151784) mastoma cells in 
culture and mouse fibroblast L cells, AraC inhibited DNA synthesis 
without inhibiting RNA or protein synthesis (129, 130). In Ehrlich 
ascites carcinoma cells inhibition of DNA synthesis by AraC was 
accompanied by a depression of glycine incorporation into histones (131).
2.1.6. Formation of 1-beta-D-Arabinofuranosylcytosine diphosphate choline 
Paterson and co-workers (168) demonstrated that AraCTP and AraCDP-
choline were the major metabolites in RPM1 6410 cells (a line of 
cultured human myeloblastoid cells). They showed that the formation 
of AraCDP-choline was preceded by the formation of AraCTP. The formation 
of AraCDP-choline is catalyzed by phosphorylcholine cytidylyltransferase.
AraCTP ♦ pliospliory lcliol iiic — . . - y  AraCDP-clio I ino + PPj
2.2. Effect of AraC on DNA Synthesis in Tetrahymena
Although AraC has been shown to be an inhibitor of DNA synthesis
the detailed mechanism of its action remains unclear. An inhibitor 
of DNA synthesis could interfere with the initiation of replication 
units, the initiation of Okazaki fragments, the elongation of 
nascent chains, the joining of Okazaki fragments or any of the 
reactions involved in the biosynthesis of DNA precursors. In this 
chapter studies on the effects of AraC on DNA synthesis in Tetrahymena 
are described.
2.2.1 Materials and Methods
2.2.1.1. Source of materials used 
Cytosine-l-fi-D-arabinoside and calf thymus DNA, were obtained
from Sigma Chemical Company. Proteose peptone and yeast extract 
were obtained from Difco. (Methyl-3H)—thymidine was obtained from 
the Radiochemical Centre at Amersham or from ICN. (2-14C)-thymidine, 
(5-3H)-cytosine-^B-D-arabinoside , and L-(methy 1-3H)-methionine were 
supplied by the Radiochemical Centre. NCS tissue solubilizer was 
bought from Hopkin and Williams. Sarkosyl was generously donated by 
Industrial Chemical Division of Ciba-Geigy Plastics and Additives 
Company. Glass Fibre filters (GF/C, 2.5 cm) were obtained from Whatman
2.2.1.2. Culture of Cells
Tetrahymena pyriformis, amicronucleate strain W, was grown at 
28°C in a defined medium (DPY) with low concentrations of phosphate 
(169). Uridine was omitted from the medium. Proteose peptone and 
yeast extract were added to a final concentration of 0.04% and 0.004% 
respectively (170). The detailed composition of this medium is shown 
in Appendix I. The medium was used for all the experiments described 
in this chapter except the one where the effect of AraC on cell 
replication was studied. In this case the cells were grown in medium 
YY which contained proteose peptone (2%), yeast extract (0.1%),
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glucose (0.5%) and FeCl3 .6H20 (5 microgram/ml).
2.2.1.3. Cell breakage
Cells were disrupted either by mechanical homogenisation or by 
sonication. For homogenisation a motor-driven Potter-Elvehjem 
homogeniser was used. The cells were cooled in ice and homogenisation 
continued until most of the cells were disrupted. The extent of 
disruption was checked under the microscope.
Mechanical homogenisation was not always satisfactory. It was 
difficult to achieve complete disruption of cells, the homogenate had 
a tendency to foam and it was difficult to work out a standardised 
procedure. Sonication was adopted as a better way of breaking cells. 
The cells were disrupted in an MSE sonicator at maximum amplitude and 
medium power. Sonication was done in three bursts each lasting five 
seconds with thirty-second intervals in between to allow the broken 
cell suspension to cool in a beaker filled with ice. With this method 
all the cells were broken, there was no problem with foaming and it 
was easy to standardise working conditions. A disadvantage of this 
method was that the cell mixture tended to heat rather more than with 
mechanical homogenisation.
2.2.1.4. Determination of radioactivity
When determining radioactivity in aqueous samples, 200-400 
microlitres of the sample was placed in scintillation vials containing 
a toluene based scintillation cocktail. The scintillation cocktail 
contained in one litre, toluene (400 ml), ethoxyethanol (600 ml),
I'I’O (4 g), and POPOI’ (0.2 g).
For samples from alkaline sucrose gradients 4 ml of scintillation 
cocktail was added to the dissolved DNA protein mixtures. The 
scintillation cocktail contained per litre of toluene, PPO (4 g) and
POPOP (0.2 g). Radioactivity was determined on a Packard scintillation
n 1 A , ,spectrometer at the JH/ C setting. The calculation of the respective 
corrected counts for 3H and in dual-labelling experiments is
shown in Appendix IV.
2.2.1.5. Effect of AraC on cell multiplication
For this experiment cells were grown in standard medium YY 
described in the section on materials and methods. Cells of concen­
tration 5 x 105 cells/ml were divided into three portions. The first 
aliquot of cells was not treated with AraC and acted as the control.
The other cells were treated with AraC to give final concentrations 
of 0.1 mM and ImM respectively. The cells were then incubated at 
28°C in an orbital shaker set at a shaking rate of 150 oscillations 
per minute. Every three hours the cell density was determined using 
a Neubauer haemocytometer.
2.2.1.6. Effect of AraC on protein synthesis
Protein synthesis was determined by measuring the incorporation 
of labelled methionine into trichloroacetic acid insoluble fractions. 
Cells were grown overnight in DPY. The cell cultures (1 x 10^ cells/ 
ml) were divided into aliquots. Cells not treated with cytosine 
arabinoside acted as the control. The other cells were treated with 
AraC to give the desired final concentrations. Labelled methionine 
(0.6 microcurie/ml, specific activity 12 Ci/mmol) was then added and 
the cells incubated at 28°C in an orbital shaker. At intervals 
samples (one millilitre) were removed from each group of cells and 
added to 57. trichloroacetic acid (one millilitre). The niixLurc was 
filtered on Whatman glass fibre discs.
After washing with trichloroacetic acid and absolute ethanol the 
discs were dried and placed in vials containing the toluene/PPO/POPOP
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scintillation cocktail used for counting the radioactivity on glass 
fibre discs.
2.2.1.7. Effect of AraC on the incorporation of thymidine into DNA 
Cells were grown for twenty-one hours in 100 ml of defined medium,
DPY. The cells used for inoculation were taken from cultures grown 
in standard medium, YY with cell concentrations of about 1.5 x 10^ 
cells/ml. (Methyl-3H)-thymidine (0.1 microcurie/ml, specific 
activity 42 Ci/mmol) was added and the cell culture divided into four 
25 ml fractions. Each fraction was treated with cytosine arabinoside 
to give the desired final concentration. At thirty minute intervals 
one millilitre samples were removed from the cell cultures and added 
to 5% trichloroacetic acid (1 ml). The mixtures were filtered on 
Whatman glass fibre filter discs. The filters were washed five times 
with 5% trichloroacetic acid and twice with 96% ethanol. After drying 
the filters were placed in vials containing the toluene/PPO/POPOP 
scintillation cocktail used for the determination of radioactivity 
on glass fibre discs.
2.2.1.8. Sedimentation of DNA intermediates on alkaline sucrose gradients 
For experiments in which alkaline sucrose gradients were used
cells were grown in a medium containing low concentrations of proteose 
peptones and yeast extract, DPY (see Appendix I). In standard experiments 
the cells were prelabelled overnight with (^C)-thymidine (0 . 2  microcurie 
/ml, specific activity 54 Ci/mmol). At the beginning of the experi­
ments the cells were divided into three fractions. After adding AraC 
to each group of cells to the required concentration the cells were 
incubated with the drug for thirty minutes at 28°C. After this time 
the cells were pulsed with (^H-methyl)-thymidine (1 microcurie/ml, 
specific activity 42 Ci/mmol) for thirty minutes. The cells were
chilled in ice and harvested in a bench centrifuge. The cells were 
then washed in ice-cold buffer (NaCI, 500 mM/EDTA, 50 mM/Tris HC1 
pH 7.2, 50 mM). In the early experiment the cell pellet was 
resuspended in distilled water and applied to the top of an alkaline 
sucrose gradient ( 5 - 20%). At the bottom of each gradient was a 
4 ml cushion of 40% sucrose. 400 microlitres of sarkosyl (1.25% 
in 1 M sodium hydroxide) was added and the gradients were left at 
4°C for thirty minutes.
In the later experiments, the cells suspended in distilled water 
were placed in a small (5 ml) wide-mouthed conical flask. After 
adding 400 microlitres of sarkosyl the flask was gently swirled once 
or twice. The lysing cells were gently applied to the top of alkaline 
sucrose gradients. The gradients were left for twenty minutes at 
4°C. This procedure resulted in a more uniform lysis of the cells 
than the method described above.
The gradients prepared by the methods described above were 
centrifuged in a Beckman SW 25.2 rotor at 24 000 rpm for twenty-two 
hours at 4°C. Fractions (2.5 ml) were collected using a modification 
of the unit described by Oumi and Osawa (171, 172). The construction 
of the unit is shown in Appendix II. Into each fraction was added 
400 microlitres of a solution containing calf thymus DNA (100 micrograms 
/ml) and bovine serum albumin (560 microgram/ml). 5% Trichloroacetic
acid ( 1 ml) was then added to each fraction and the mixture was left 
to stand overnight at 4°C. Leaving the mixture to stand overnight in 
the cold room improved the filtration of the acid-insoluble precipitate.
The precipitates were filtered by suction on Whatman glass fibre discs.
The discs were washed five times with two ml volumes of 5% trichloro­
acetic acid. Suction was continued until most of the water was 
removed but the discs were still moist.
60
61
The moist discs were placed in scintillation vials and one millilitre 
of NCS (diluted 1 in 3 in toluene/PPO/POPOP scintillation liquid) was 
added. The contents were left to stand at room temperature for about 
two hours. When the DNA and protein precipitate had dissolved 4 ml 
of scintillation cocktail was added and radioactivity counted.
Sedimentation coefficient» were estimated according to the method
of McEwen (173). The detailed procedure for calculating sedimentation
coefficients by this method is outlined in Appendix III.
2.2.1.9. Characterization of thymidine incorporation as a measure 
 of DNA synthesis_____________________
Cells were labelled overnight with (^C)-thymidine (0.02 micro- 
curie/ml specific activity 54 Ci/mmol). The cells were harvested by 
centrifugation at 5 OOOg and the cell pellet resuspended in distilled 
water in a total volume of 5 ml. The cells were then broken by 
sonication. DNA was separated from the other cell fractions (174).
2.5 ml of ice-cold perchloric acid (0.6 M) was added to the sonicated 
cells and the mixture allowed to stand for ten minutes. The mixture 
was then centrifuged in a bench centrifuge and the supernatant discarded. 
The precipitate was washed twice with 5 ml cold perchloric acid (0.2 M). 
After decanting the perchloric acid and allowing the tube to drain 
for a few minutes, 4 ml of potassium hydroxide solution (0.3 M) was 
added and the mixture incubated at 37°C for one hour to dissolve all 
the solid materials. The tube was then chilled in ice for fifteen 
minutes. After adding 5 ml perchloric acid (0 . 6  M) the mixture was 
centrifuged and the supernatant kept. The precipitate was washed twice 
with 5 ml cold perchloric acid (0.2 M). The three supernatants were 
combined. The precipitate was made up to 0.5 ml with distilled water.
The radioactivity in the supernatant and in the pellet was 
determined. Because RNA is sensitive to alkaline hydrolysis and DNA
lì 2
Figure 2.3
Effect of AraC on cell multiplication in Tetrahymena
Cells were incubated with and without AraC at 28°C. At three 
hour intervals cells were removed and the cell density determined 
using a Neubauer haemocytometer.
_____ a Control
AraC (0.1 mM)
-o AraC (1 mM)
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is not the radioactivity in the supernatant corresponds to KNA and 
that in the precipitate to DNA.
2.2.2. Results and Discussion
Unless otherwise indicated, in this and subsequent chapters all 
the results reported were obtained from at least two experiments each 
of which was done in duplicate.
2.3.1. Effect of AraC on cell multiplication
The effect of AraC on cell multiplication in Tetrahymena is shown 
in Figure 2.3. At concentrations below 0.1 mM, AraC did not produce 
noticeable inhibition of cell multiplication in Tetrahymena. At a 
concentration of 1 mM AraC effectively stopped cell division for 
about six hours (two generations). After this time the cells started 
to divide again at a nearly normal rate. Lower concentrations of the 
drug inhibited cell replication for shorter periods before division 
resumed at a normal rate.
For AraC to stop cell replication an inhibitory concentration of 
the drug must be maintained within the cell (162). The maintenance 
of this concentration of AraC depends on the rate at which the drug 
is passed through the cell membrane, the rate at which it is converted 
to inactive products after absorption and the rate at which it is 
phosphorylated.
The ability of cells to recover from the effects of even high 
concentrations of AraC may provide a clue to the loss of effectiveness 
of this drug when it is used in clinical situations. It is unlikely 
that recovery is associated with interference with the passage of AraC 
into cells. Passage of AraC and other nucleosides into cells appears 
to be free and unhindered and does not involve active transport (162).
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The recovery could be due to an acquired resistance to the drug by 
cells or to the cellular concentration of the drug falling below that 
required to inhibit cell division. Cellular AraC could be inactivated 
by conversion to Aral! by a cytidine deaminase (175).
2.3.2. Effect of AraC on DNA synthesis
The performance of and the interpretation of results from 
experiments with alkaline sucrose gradients requires some care. After 
lysis of cells by sarkosyl in the alkaline sucrose solution DNA is 
released and progressively dissociated from the other cell components. 
At the alkaline pH complementary strands of DNA separate. Both lysis 
and strand separation depend on cell type, cell concentration, time, 
temperature and ionic strength (176). Exposed DNA is sensitive to 
degradation by mechanical shearing forces. In alkaline solution DNA 
is also affected by visible light (177).
A completely different problem is the evaluation of sedimentation 
coefficients. Calculations are generally based on the method described 
by Studier (178). Under certain conditions drag and centrifugal 
forces can distort the random coil configuration of DNA. The apparent 
sedimentation coefficients determined will then be less than predicted 
by Studier's equation (179).
The effect of AraC on DNA in Tetrahymena is shown in Figures 2.4 
and 2.5. When cells are pulsed with tritiated thymidine in the absence 
of AraC the tritium label appears in DNA of all sizes as shown in 
Figure 2.3. When the cells are pulsed with tritiated thymidine in the 
presence of AraC (0.5 mM) the label appears in DNA of high and inter­
mediate molecular weights. In Figure 2.4 it can be seen that only a 
small fraction of the label is found in low molecular weight DNA.
Two apparently conflicting results have been reported of the 
effect of AraC on DNA synthesis. Dijkwel and Wanka (180) reported
*  £
Figure 2.4
Analysis of DNA intermediates on alkaline sucrose gradients
Cells, prelabelled with ^C, were pulsed with labelled thymidine 
for thirty minutes in the absence of AraC. After harvesting the 
cells by centrifugation the cell pellet was placed onto an alkaline 
sucrose gradient ( 5 - 20%) and the cells lysed with sarkosyl. After 
centrifugation in an SW 25.2 rotor fractions were collected as 
described in the text. DNA in each fraction was precipitated with 
TCA and filtered onto Whatman glass fibre discs. Radioactivity 
was counted after dissolving the DNA precipitates in NCS. Although 
the experiment was done several times the results reported here are 
from one typical set of results. Variation in the number and size 
of the fractions collected made it impossible to combine results 
from different runs.
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Figure 2.5
Effect of AraC on the formation of DNA intermediates
Cells prelabelled with were treated with AraC (1 mM) for 
thirty minutes. The cells were then pulsed with) )Td for thirty 
minutes and then treated as described in Figure 2.A.
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that in calf liver cells AraC caused a preferential inhibition of chain 
polymerisation rather than termination of nascent chains. However,
Fridland observed that in human lymphoblasts AraC had no effect on 
DNA chain elongation or the joining of molecules that had already 
been initiated (181). He concluded that AraC inhibited the initiation 
of DNA replication units.
In this work I observed the depletion of low molecular weight 
DNA but not of DNA of high and intermediate molecular weight. These 
results indicate that in Tetrahymena, AraC inhibits the initiation 
step of DNA synthesis. Chains that have already started to replicate 
do not appear to be affected by AraC.
2.3.3. Effect of AraC on the incorporation of labelled precursors into
DNA and protein
Figures 2.6 and 2.7 show the effect of AraC on the incorporation 
of labelled thymidine and methionine into DNA and protein respectively.
Low concentration of AraC did not affect the incorporation of thymidine 
into either DNA or protein. At higher concentration (greater than
0.25 mil) the rate of DNA synthesis was depressed. Even very high 
concentrations (6mg/25ml) had practically no effect on protein synthesis 
during the three-hour duration of the experiments. This shows that the 
effect of AraC is directly on the DNA replicating process rather than 
indirectly on protein synthesis.
2.3. A. Thymidine incorporation as a measure of DNA synthesis 
From Table 2.1 it can be seen that when cells are treated with
labelled thymidine about 90Z of the label appears in the DNA fraction.
Little of the label is found in RNA. The 10% of the labelled thymidine 
not recovered in DNA may be in other metabolic pools. The observed 
distribution of radioactivity indicates that on the whole thymidine 
incorporation can be taken as a reasonable measure of DNA synthesis.
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Figure 2.6
Effect of AraC on the incorporation of (^H)methionine into protein
Protein synthesis was measured by determining the amount of 
labelled methionine incorporated into acid-insoluble fractions. The 
incorporation of labelled methionine was measured in the presence 
and absence of AraC.
o Control
AraC (1 mil)
In this graph and those that follow the experimental points plotted are 
means plus or minus the standard deviation which is indicated by error
Time (minutes)
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Figure 2.7
F.ffect of AraC on the incorporation of (methyl-^H) thymidine into DNA
DNA synthesis was determined by measuring the incorporation of 
labelled thymidine into acid-insoluble fractions. At concentrations 
lower than 10-^M AraC did not produce detectable inhibition of DNA 
synthesis as measured by thymidine incorporation.
----- O-----  Control
----- •-----  AraC (6.25 x 10"5M)
AraC (2.5 x 10-4M)
into DNA
on of
rations
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Fraction Percent radioactivity
Whole cells 10 0
DNA 89.9 ± 0.5
RNA 0 . 0 1  ± 0 . 0 0 2
Other (calculated) 10.1 ± 0.5
Table 2.1 Thymidine incorporation as a measure of 
DNA synthesis
Cells were labelled with (^C)-thymidine and the DNA 
and RNA fractions prepared as described in the text. 
The radioactivity in the DNA and RNA fractions was 
expressed as a fraction of the total radioactivity in
whole cells.
CHAPTER 3
3.1 Metabolism of Cytosine arabinoside in Tetrahymena
Although it is widely accepted that AraC stops cell division 
and causes cell death (162) by interfering with DNA synthesis there 
is disagreement about the detailed mechanism of action. There is 
still some confusion as to whether the primary determinant of the 
therapeutic efficacy of AraC is the cellular concentration of AraC 
itself or the phosphorylated metabolite AraCTP (175). Steuart and 
Burke found an inverse relationship between responsiveness to AraC 
and the level of cytidine deaminase in the cell-free extracts of 
acute leukaemia blast cells. However, other workers have found that 
the response to AraC was primarily correlated to the total pool of 
nucleotides or to cytidine kinase activities (182). Chou and co­
workers found that acute myeloid leukaemic (AML) cells from patients 
who were sensitive to AraC treatment produced more AraCTP than cells 
from patients unresponsive to treatment by the drug. However, the 
ability to synthesize appreciable amounts of AraCTP is not sufficient 
to account for the therapeutic response to AraC. Samples from 
relapsed patients previously sensitive to AraC treatment, produced 
high levels of AraCTP.
In Novikoff cells it was found that the rate of transport of 
AraC was much higher than its phosphorylation (183). These workers 
concluded that phosphorylation was the limiting step in the incorp­
oration of AraC into the nucleotide pool.
Although AraC can be converted into inactive AraU by cytidine 
deaminase in crude cell preparations the expression of degradative 
enzyme activity may not be fully expressed in intact cells. Experiments 
done with cell-free extracts may produce misleading results about the
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metabolism of AraC in whole cells.
3.2 Materials and Methods
3.2.1. Sources of materials
(5-^n)-Cytosine-B-D-arabinoside was obtained from the radiochemical
Centre at Amersham. Unlabelled AraC, AraCMP, AraCTP were supplied by 
the Sigma Chemical Company. Prefilled Econo-Columns of Agl-X8 (anion 
exchange agent in chloride form, 200 - 400 mesh) and AG50W-X8 (cation 
exchange agent in hydrogen form, 200 - 400 mesh) were purchased from 
BioRad. Unprocessed Dowex 50 (cation exchange resin in hydrogen form, 
200 - 400 mesh) was obtained from Sigma Chemical Company. Tetrahydro- 
uridine was obtained from Calbiochem. Proteose peptones and yeast 
extract were obtained from Difco.
3.2.2. Culture of cells
Tetrahymena pyriformis. amicronucleate strain W, was grown in 
cultures containing proteose peptones (2%), yeast extract (0 .1 %), 
glucose (0.5%), and FeCl3 .6H2 0 (5 microgram per ml). This medium was 
used for most work and is referred to in this report as the standard 
medium YY. For most work cells were grown in 500 ml of medium 
contained in 2.5 litre conical flasks.
The desired volume of cell inoc ulum was calculated from the 
equat ion
v
where v is the volume of inoc ulum required, y the desired cell 
concentration in cells/ml, X the concentration of cells in the stock
culture, t the time in hours from the time of inoculation to the time 
of harvesting the cells at concentration y and V the volume of the 
cell culture.
The flasks were placed in an orbital shaker operating at a shaking 
rate of 150 oscillations per minute. The temperature was maintained 
at 28°C. The cells were generally harvested during the log phase 
when their concentration was between 2 and 4 x 10^ cells/ml. If 
stationary phase cells were required, harvesting was done when the 
cell concentration was over 1 0 6 cells/ml.
To determine cell concentration the cells were first diluted with 
an equal volume of formalin solution (20% in 0.01 M phosphate buffer 
pH 7). The fixed cells were then counted in a Neubauer counting 
chamber.
3.2.3. Preparation of Dowex 50 resin
Dowex 50 resin, in the hydrogen form, had a yellow discolouration 
when supplied. The material was first washed in sodium hydroxide 
(1 M). After rinsing in water to remove all the sodium hydroxide the 
resin was washed in hydrochloric acid (1 M). After removing excess 
acid by rinsing in water, the resin was converted to the ammonium form 
by adding ammonia (1 M). Finally the resin was washed in water until 
the pH was between 4 and 5. The whole washing process was done 
batchwise. The prepared resin was stored under water at room temperature.
3.2.4. Separation of cytosine arabinoside metabolites
Cells at a concentration of about 106 cells per ml and grown in 
standard medium YY wore incubated in the presence of labelled cytosine 
arabinoside (0.02 microcurie per ml, specific activity 24 Ci/mmol).
The cells were harvested at 3000 g and then sonicated as described in 
Chapter 2. One volume of 5% trichloroacetic acid was added to the 
sonicated cells and the mixture allowed to stand for two and a half
hours. The mixture was then centrifuged in a bench centrifuge to 
remove acid-insoluble material. The acid-insoluble material was 
placed in a scintillation vial, dissolved in NCS and its radioactivity 
counted.
The supernatant was applied onto a pre-filled Econo-Column 
containing 0.7 x 4 cm of AG1-X8 anion exchange resin. The metabolites 
of AraC were separated by a method based on that used to separate 
uridine and its metabolites (140, 184). Stepwise elution of the 
column with water, 0.15, 0.3 and 1 M ammonium bicarbonate separated 
the nucleosides (AraC and AraU), AraCMP, AraCDP and AraCTP. Samples 
(400 microlitres) were taken from each fraction collected and placed 
in the toluene/ethoxyethanol/PPO/POPOP scintillation cocktail for 
the counting of radioactivity.
To separate AraC from AraU the fractions containing most of the 
radioactivity when the AG1-X8 column is eluted with water were pooled 
and applied onto an AG50W cation exchange column. The column was 
eluted with water and then ammonia (1 M). Samples (400 microlitre) 
were removed from each fraction collected and radioactivity counted 
as above.
3.2.5. Assay for cytidine deaminase activity with cytosine arabinoside
as the substrate_________________________
The cytidine deaminase activity of Tetrahymena was determined using 
tritiated cytosine arabinoside as the substrate. At first cytidine 
deaminase activity was assayed following the method described by 
Rothman and co-workers (185). Enzyme activity was estimated by 
measuring the amount of labelled uracil arabinoside formed by the 
deamination of cytosine arabinoside.
Cells were grown in standard medium YY and harvested when the cell 
concentration was about 10^ cells per ml. The cell pellet was resuspended
in buffer (Tris-HCl 0.5 M, pH 8) and sonicated. The sonicated cells 
were used in enzyme assays. The assay mixture contained in a total 
volume of 150 microlitres, 100 microlitres enzyme mixture, 30 
microlitres Tris-HCl pH 8 , labelled cytosine arabinoside (1.25 
microcurie, specific activity 24 Ci/mmol). The mixture was incubated 
for twenty minutes at 28°C. The reaction was stopped by adding 50 
microlitres hydrochloric acid (3M). Ten microlitres each of 
unlabelled marker AraC (10 mM) and AraU (41 mil) was added to the 
mixture. After centrifugation 150 microlitres of the supernatant 
was applied onto a Dowex 50 column (1 x 10 cm). In later assays the 
prefilled AG50W-X8 columns were used. The column was eluted with 
water and 2.5 ml fractions collected. When the first radioactivity 
had been eluted and the counts were close to background the column 
was eluted with an ammonia solution (1 M) and fractions collected 
again. 400 microlitres of each fraction was added to the toluene/ 
ethoxyethanol/PPO/POPOP scintillation cocktail for the counting of 
radioactivity.
The radioactivity coming out when the column was eluted with 
water corresponded to uracil arabinoside which carries no charge. The 
radioactivity which was eluted by ammonia corresponded to cytosine 
arabinoside whose amino group carries a positive charge at low pH 
but which loses its charge in ammonia.
For routine work the method just described was too long to be 
practicable. A simple and quicker method was developed. Essentially 
the new method was batch operation which involved mixing the resin and 
the supernatant from the reaction mixture and allowing equilibrium to 
be established. Enzyme, buffer and labelled AraC were incubated at 
28°C for twenty minutes as in the previous method. After stopping
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the reaction with acid the reaction mixture was centrifuged and 
150 microlitres of the supernatant were removed and placed into test 
tubes containing 1 gram of moist resin. One ml of distilled water 
was added and the mixture agitated in a vortex mixer. The mixture 
was either allowed to stand for about ten minutes or centrifuged for 
one minute. 400 microlitre samples were then placed into vials 
containing scintillation liquid with ethoxyethanol. Radioactivity 
was counted as above.
3.3 Results and discussion
3.3.1. Separation of cytosine arabinoside metabolites
Figures 3.1 and 3.2 show the separation of AraC and its 
metabolites by ion exchange chromatography. When the anion exchange 
column (AG1-X8) was used most of the radioactivity passed through 
when the column was eluted with water. This radioactivity correspon­
ded to cytosine arabinoside and uracil arabinoside. Only a small 
fraction of the AraC was converted to AraCMP, AraCDP or AraCTP.
Only a tiny amount of the putative active agent, AraCTP, was formed.
The fractions corresponding to AraC and Aral) were pooled and the 
two nucleosides separated on a cation exchange column as shown in 
Figure 3.2. Uncharged AraU was eluted from the column with water.
AraC came off when the column was eluted with 1 M anmonia.
The present results show that whereas AraC was rapidly converted 
to AraU in cell homogenates only a tiny fraction is phosphorylated. 
Although results obtained with cell homogenates may not apply to 
intact cells it is probable that intact Tetrahymena cells also 
rapidly convert AraC to AraU. Most of the AraC would then be 
deaminated before the accumulation of AraCTP. It is possible that the
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Figure 3. 1
Fractionation of AraC metabolites on AG1-X8 anion exchange resin
Cells labelled with (-*H) cytosine arabinoside were sonicated.
After addition of TCA acid-insoluble material was removed by spinning 
in a bench centrifuge. The supernatant was applied onto an AG1-X8 
column. After elution with water AraCMP, AraCDP and AraCTP were 
eluted with 0.15, 0.3 and 1 M NH4HCO3 at a, b, and c respectively.
The peaks A, B, C, and D are for AraC/AraU, AraCMP, AraCDP and
AraCTP respectively. Although the experiment was done several times
the results shown here and also in Figures 3.2 and 3.3 are from one
typical experiment. It was not possible to collect the same number
of fractions all with equal volumes all the time. The precise
position of the peaks, therefore, differed slightly in different
sets of the same experiment. Cold AraC» AraU, AraCMP, AraCDP and AraCTP war«
used as standards in identifying radioactivity p«aka.
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Figure 3.2
Separation of AraC and Aral) on AG50-X8 cation exchanger.
Fractions from peak A in Figure 3.1 were pooled and applied onto 
an AG50-X8 column. The column was first eluted with water and then 
with ammonia (1 M) at the point indicated by the arrow. Peaks E 
and G represent Aral! and AraC respectively.

amount of AraCTP formed is even less than indicated in Figure 3.1.
The peak for the triphosphate could also include AraUTP which 
presumably would not be effective in inhibiting cell division and 
causing cell death.
Figure 3.10 and 3.11 show the separation of AraC metabolites 
from cell preparations incubated with labelled cytosine arabinoside 
and THU (3 x 10”^M). It can be seen in Figure 3.10 that the presence 
of THU did not lead to any increase in the amount of phosphorylated 
AraC formed. When fractions from the nucleoside peak were analysed 
on the cation exchanger most of the radioactivity was found in the 
AraC peak (Figure 3.11). Only 2.5% of the total nucleoside radio­
activity was recovered in the AraU fraction. The presence of THU 
markedly reduces the deamination of AraC to AraU. However, the 
increased cytosine arabinoside pool does not lead to a corresponding 
increase in the amount of phosphorylated AraC formed. It appears 
that phosphorylation is the critical step in the effectiveness of 
AraC in inhibiting DNA replication.
3.3.2. Cytidine deaminase
Figure 3.3 shows the result of a cytidine deaminase assay on an anion 
exchange column using cytosine arabinoside as the substrate. By 
eluting the column with water and ammonia clean separation of AraC 
and AraU was effected. Although the procedure was simple, it was 
time-consuming for routine use. The assay for cytidine deaminase by 
this method was not, therefore, used for routine purposes.
The determination of the optimum amount of resin required for 
the assay of cytidine deaminase by the batch process is shown in 
Figure 3.4. Nearly 60% of the AraC in the supernatant was bound by
0.2 g of resin. The amount of AraC bound by the resin then increases
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Figure 3.3
Cytidine deaminase assay on an ion exchanger with cytosine arabinoside
as the substrate ______________________
Labelled cytosine arabinoside was incubated with enzyme 
preparations as described in the text. The reaction was stopped by 
addition of acid. After centrifugation the supernatant was applied 
onto an AG50-X8 column which was then eluted with water and then with 
ammonia (1 H) at the point indicated by the arrow.
(A) Column eluted after AraC was incubated with enzyme.
(B) No enzyme control.
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Figure 3.4
Determination of optimum amount of resin required for cytidine
deaminase assay._____________________
Labelled cytosine arabinoside was added to tubes containing 
increasing amounts of AG50-X8 cation exchanger and one millilitre of 
water. After agitation to ensure thorough mixing the tubes were 
centrifuged for about a minute in a bench centrifuge. The radio­
activity in the supernatant was then counted and was a measure of 
the cytosine arabinoside that remained unbound.
120 6 0 8 10
Weight of cation exchange resin
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slowly to about 80% for 0.8 g resin. After this an increase in the 
amount of resin does not result in a substantial increase in the 
amount of AraC bound, for routine purposes one gram of resin was 
used. Although it was difficult to transfer reproducibly equal amounts 
ol resin into the assay tubes iL can be seen from figure '1.4 that a 
40% variation of the amount of resin from 1 g should not result in 
more than 8% variation in the amount of AraC bound.
Figure 3.5 shows the time course for the cytidine deaminase 
reaction assayed by the new method. The reaction is nearly linear 
for about twenty minutes. A reaction time of twenty minutes was used 
for the assays described below. The effect of AraC concentration on 
the rate of reaction is shown in Figure 3.6.
The inhibition of Tetrahymena cytidine deaminase by tetrahydro- 
uridine is shown in Figure 3.8. The deaminase activity is
almost totally inhibited by 4 x 10” tetrahydrouridine. This
result is similar to the findings of Camiener who reported that 
tetrahydrouridine concentrations of 10"^ to 10 inhibited 95% of 
the deaminase activity in preparations of mouse kidney, rhesus 
monkey liver and actinomycete mycelium (186). The for tetrahydro­
uridine was determined by measuring deaminase activity at two 
concentrations of AraC in the presence of increasing amounts of 
inhibitor. The Dixon plot for these results is shown in
Figure 3.9. The value obtained (8 x 10-8M) is considerably lower 
than the values reported by Camiener (10”  ^- 10“-*M) but somewhat 
closer to the values reported by Furner and Mellett (10”7 - 10 ®M)(187).
The assay developed for the assay of cytidine deaminase was simple,
* * s
rapid and convenient for most routine purposes 
it is necessary to recover unreacted cytosine
. Only in cases where 
arabinoside is the
column procedure worthwhile.
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Figure 3.5
Time course of the cytidine deaminase reaction with cytosine arabinoside
as substrate
Labelled cytosine arabinoside was incubated with enzyme as described 
in the text. At five minute intervals TCA was added to some of the 
reaction mixtures. After removal of acid-insoluble material by 
centrifugation AraC was then separated from AraU on AG50-X8 resin 
by the batch operation described in the text.
Whan tha supernatant from tha centrifuged reaction mixture Is added 
to the ion exchange resin most of tha AraC is bound to tha resin. A 
small fraction of tha total AraC and all tha AraU remains in tha 
supernatant. In tha no enzyme control all tha radioactivity in tha 
supernatant is due to AraC only. Tha difference between assays in 
which the enzyme is present and the no enzyme control is a measure of 
the amount of AraU formed from the deamination of AraC.
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Figure 3.6
Effect of AraC concentration on the rate of cytidine deaminase reaction
Cytidine deaminase activity was determined following the batch 
procedure developed. Assay mixtures were incubated for twenty minutes
at 28°C.


Figure 3.8
Effect of tctrahydrouridine on the deamination of AraC by cytidine
deaminase _______
Labelled cytosine arabinoside was incubated with enzyme preparations 
in the presence of increasing amounts of tetrahydrouridine. The 
deamination of cytosine arabinoside was followed by measuring the 
amount of Arall produced.

Figure 3.9
Determination of for tetrahydrouridine in the deamination of AraC
The rate of deamination of AraC was measured at two concentrations 
of AraC (3.8 £ 7-6jjM)in the presence of increasing amounts of tetra­
hydrouridine. For the two separate sets of experiments 1/V was 
plotted against the tetrahydrouridine concentration. was then
obtained from the intersection of the two experimental lines as shown 
on the graph.
-o- 3.8 micromolar AraC
7.6 micromolar AraC
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Figure 3.10
Effect of tetrahydrouridine on the metabolism of AraC in Tetrahymena
Cytosine arabinoside was incubated with enzyme preparations in 
the presence of tetrahydrouridine (3 x 10”^M)» After adding acid and 
removing acid-insoluble fractions by centrifugation the supernatant 
was applied onto an AG1-X8 column. The column was washed with water 
to elute AraC and AraU. AraCMP, AraCDP and AraCTP were then 
separated by eluting with 0.15, 0.3 and NH^HCOj at A, B, and C 
respectively. The experiment was done several times but the results 
shown here and in Figure 3.11 are from one typical experiment.
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Figure 3.11
Fractionation of the nucleoside peak from Figure 3.10 on AG50-X8
cation exchange resin__________________
Fractions containing the nucleoside peak shown in Figure 3.10 
were pooled and applied onto an AG50-X8 column. The column was 
washed with water to elute any AraU present and with ammonia (1 M) 
at the point shown by the arrow to elute cytosine arabinoside.

CHAPTER 4
4.1 The use of synthetic template-primers
In bacteria numerous mutants defective in various aspects of DNA 
synthesis have been used to determine the function of DNA polymerases. 
Except for a few exceptions no such mutants are available for most 
eukaryotic cells. In these organisms less direct methods for studying 
the role of DNA polymerase have had to be used. One such approach has 
been to investigate the use of synthetic templates and primers by 
DNA polymerases.
All DNA polymerases described require a preformed initiation 
site. In addition to a requirement for 3'-hydroxyl termini the 
enzymes need some double-stranded structure for maximal activity. This 
may be provided by using degraded DNA or oligonucleotide initiated 
homopolymers (188). Work in many laboratories suggests that RNA 
fragments may be involved in the initiation of DNA synthesis (189).
In DNA polymerising systems four classes of template-primers can 
be considered:
(a) polyribonucleotide template-ribonucleotide primer,
(b) polyribonucleotide template-deoxyribonucleotide primer,
(c) polydeoxyribonucleotide template-deoxyribonucleotide primer, and
(d) polydeoxyribonucleotide template-ribonucleotide primer (188).
The ability of DNA polymerases to use these template-primers might 
provide a clue to the cellular role of these enzymes. Class (a) 
template-primers would be used by DNA polymerases which are able to 
copy an RNA strand and extend an RNA primer. Such enzymes would be 
reverse transcriptases. As far as I am aware no reverse transcriptases 
of this type have been described.
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The reverse transcriptases that have been described use class (b) 
type template-primers. Ever since the discovery of reverse 
transcriptase associated with RNA tumour viruses (190, 191) and in 
human leukaemia cells (192) many workers have studied the ability of 
normal eukaryotic DNA polymerases to copy RNA templates. In addition 
to reverse transcriptase, DNA polymerase beta and DNA polymerase 
gamma can also use class (b) template-primers. Some confusion has 
arisen as a result of workers prematurely claiming to be able to 
distinguish the enzymes that can copy RNA by the use of synthetic 
template-primers. At present the general picture seems to be as 
follows. Some class (b) template-primers are used by both reverse 
transcriptases and normal DNA polymerases. Poly(A) .poly(dT) is an 
effective template primer for both viral and cellular DNA polymerases 
(193). Because it is non-specific poly(A).poly(dT) cannot be used 
to distinguish between reverse transcriptase and the other polymer­
ases.
Reverse transcriptases and other DNA polymerases can be 
distinguished by the use of oligo homopolymers such as poly(A)oligo- 
(dT),_ Whereas viral polymerases prefer poly(A) .oligo(dT), DNA
polymerase from normal human lymphocytes showed no detectable 
activity (193). Although DNA polymerase beta is able to use primed 
poly(A) it cannot copy natural RNA or rCndGj. Poly(C).oligo(dG) has 
been considered to be specific for viral transcriptases (194, 195,
196). However, Spadari and Weissbach have purified gamma DNA 
polymerase from HeLa cells which effectively uses poly(C).oligo(dG)
(42). Poly(2'-O-methylcytidylate).oligodeoxyguanylate (polyC^.oligo dG) 
is an effective template-primer for RNA tumour virus reverse 
transcriptases which promises to be a specific one. It has been
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found that nuclear DNA polymerase . imma can copy poly(C).oligo(dG) but 
not poly(Cm).oligo(dG) (197).
Some care is required when using synthetic templates to character­
ise the different DNA polymerases. In the presence of Mn, for example, 
at lease one cellular DNA polymerase will use poly(A).(dT)^ more 
effectively than poly(dA).oligo(dT) g. There is no indication, 
however, that this is a true reverse transcriptase (194).
DNA polymerases which use class (c) template-primers extend a 
DNA primer and copy a DNA template. This class of template-primer 
includes activated DNA, denatured DNA, polyd(A-T), and oligodeoxy- 
nucleotide-initiated polydeoxynucleotides such as poly(dA).oligo(dT).
Polyd(A-T) is interesting because it can be synthesized de novo 
by DNA polymerase alpha (64). This synthesis is inhibited by dGTP 
and dCTP and is stimulated by unwinding protein. Polyd(A-T) is able 
to act as template-primer even though it is double-stranded at the salt 
concentration and temperature used.It could provide a single strand 
template by one or both of two mechanisms.
Polyd(A-T) can be converted into a single strand form by unwinding 
protein. The maximum amount of single strand template is provided when 
the polyd(A-T) is fully complexed to the unwinding protein. This happens 
when the unwinding protein/polyd(A-T) ratio is about 8 to 1 (64). An 
amount of unwinding protein beyond that required to convert all the 
template to a single-stranded form is inhibitory.
A second method by which polyd(A-T) can provide a single-stranded 
template is by strand slippage. The short repeating sequence allows 
movement of either the 3'-OH or the 5' end along the chain to expose 
a single-stranded template. As strand slippage cannot occur under 
conditions which favour breaking and reforming of hydrogen bonds it
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cannot occur under conditions which favour the stability of the double 
helix.
Since magnesium^lfnd low temperatures favour the stability of 
the double helix this could explain the lower magnesium optimum and 
the higher temperature optimum Cor polyd(A-T) replication as compared 
to that for activated DNA replication (198).
Although polyd(A-T) synthesis can occur in the absence of unwinding 
protein, the absence of unwinding protein results in longer lag periods 
before synthesis than when the protein is present. A number of 
polynucleotides systems can stimulate the de novo synthesis of polyd(A-T). 
Activated and native DNA are very effective in reducing the lag period 
before synthesis. The lag periods are a little longer with denatured 
DNA. (dT)j2_^g*P°ly(dA) or polyribonucleotides are without effect.
In this work denatured calf thymus DNA, polyA.polydT, polyA.alT^Q , 
polydA.dTj0 and polyd(A-T) were used. These template-primers were chosen 
on the basis of their usefulness in assigning roles to DNA polymerase 
activities and cost. Denatured DNA, polydA.dT^^, and polyd(A-T) 
were used as general template-primers for DNA polymerases (52). 
PolyA.polydT was used as the tepplate-primer used by DNA polymerases 
similar to DNA polymerase beta and gamma or to reverse transcriptases (21).
4.2. N-ethylmaleimide and DNA polymerases
A number of eukaryotic DNA polymerases are inactivated by thiol 
reagents (53). This has generally been interpreted to mean that 
sulphydryl groups are required for polymerase activity. N-ethylmaleimide 
(NF.M) is the best known of a number of N-substituted maleimides which 
react with thiol groups as shown below.
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Although it is probable that NEM has a high selectivity for thiol 
groups the formation of adducts with sulphide, sulphite and thiosulphate 
and the slow reaction with peptide amino end groups, the amino group 
of lysine and the imidazole group of histidine, limit its use as a 
specific reagent (199).
4. 3 Materials and methods
4.3.1. Sources of materials
NEM, AraCTP, calf thymus DNA, the deoxyribonucleotides dATP, dCTP, 
dCTP and unlabelled TTP were obtained from Sigma Chemical Company.
PolyA.polydT was bought from P. L. Biochemicals. PolydA.dT^g,
3polyd(A-T) and poly(dA-(methyl- H) dT) were supplied by Miles Laboratories.
3(methyl- H)TTP was supplied by the Radiochemical Centre at Amersham.
Glass fibre discs (GF/C, 2.5 cm) and DEAE-cellulose (microgranular, 
pre-swollen DE52) were obtained from Whatman. Nonidet P40 was 
supplied by the British Drug Houses. PolyA.dT^ was obtained from 
Bochringer Manhcim.
4.3.2. Preparation of denatured DNA template-primer
Calf thymus DNA (1.5 mg/ml in 0.02 M Tris and 0.02 M NaCl) was 
heated in a boiling water bath for ten minutes (200). The container 
was then quickly cooled in ice to obtain denatured DNA. Denaturation
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of DNA was done immediately before each DNA polymerase assay.
A.3.3. Nuclease assays
Nuclease activity was determined by measuring the amount of
3acid-soluble products formed from poly (dA-(methyl- H)dT) (201, 202).
In a total volume of 90 microlitres the assay mixture contained
glycine-KOH buffer pH 8.9 (3 micromoles), dithiothreitol (0.1 micro-
3moles), magnesium chloride (0.5 micromoles), poly (dA-(methyl- H)dT)
(0.2 microcurie, specific activity 18.6 Curie/mol.). Reaction was 
started by adding 10 microlitres enzyme preparation and the mixtures 
incubated at 28°C.
At the end of the reaction 100 microlitres of a solution 
containing DNA (1 mg/ml) and BSA (56 mg/ml) was added. The reaction 
was then stopped by adding 150 microlitres of TCA (0.5 M) The 
mixtures were allowed to stand in an ice bath for about five minutes. 
Acid-insoluble material was removed by spinning in a bench centrifuge 
for one minute. 300 microlitres of the supernatant were then removed 
and placed in vials containing the toluene/ethoxyethanol/PPO/POPOP 
scintillation cocktail for the counting of radioactivity.
A.3.4. DNA polymerase assays
DNA polymerase activity was assessed by measuring the amount of 
3(methyl- H)TTP incorporated into acid-insoluble material (203). In 
a total volume of 200 microlitres the assay mixture contained HC1 
(4 micromoles), Tris-HCl pH 7.6 (11 micromoles), magnesium chloride 
(1.8 micromoles), 2-mercaptoethanol (0.6 micromoles), F.DTA (0.03 micro­
moles), dATP, dCTP, dCTP (24 nmoles each, (methyl-JII)TTP (0.36 nmoles, 
specific activity 2.5 Ci/nmol), denatured calf thymus DNA (15 microgram). 
In some experiments manganese replaced magnesium as the metal ion 
and synthetic polynucleotide systems replaced DNA as the template-
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primer. Reaction was started by adding 100 microlitres of enzyme 
preparation. The mixture was incubated at 28°C for twenty minutes.
After incubation, 50 microlitre samples were removed and spotted 
onto Whatman glass fibre discs which were immediately immersed in 
ice-cold TCA (5%). The discs were then washed five times in fresh 
TCA and twice in cold absolute ethanol.
Alternatively 50 or 100 microlitre samples were spotted onto 
glass fibre discs in a Buchner funnel. The discs were then washed 
with TCA and ethanol with suction.
The washed discs were dried and placed in a scintillation cocktail 
containing toluene, PP0/P0P0P for the counting of radioactivity on 
glass fibre discs. The specific activity of the enzyme was calculated 
as nmoles (methy1-^H)TTP incorporated per minute per mg protein.
When the effect of NEM and AraCTP on DNA polymerase activity was 
studied, quantities of these substances were added to the DNA 
polymerase cocktail in a total volume of 240 microlitres.
4.3.5 Assay for terminal deoxynucleotidy1 transferase activity
Terminal deoxynucleotidy1 transferase activity was assayed by 
measuring DNA polymerase activity in the presence of TTP only as the 
deoxynucleotide substrate (204). Otherwise the assay was done in the 
same way as the DNA polymerase assay.
4.3.6. Preparation of enzyme fractions
Cells at a concentration of 2 to 4 x 10'’ cells/ml were harvested 
by centrifugation at 5000 g for 10 minutes. The cell pellet was 
resuspended in 0.25 H sucrose/10 mM MgCl2 to give a final volume of 
5 ml. Nuclei were then prepared by a modification of the method of 
Mita (205). The cell suspension was treated with one volume of 
Nonidet P40 (IE in 0.25 M sucrose/10 mM MgCl2 > for one minute. In
Cells packed by centrifugation at 5000 g for 10 minutes
Pellet suspended in 0.25 M sucrose/10 mM MgCl2 to make 5 ml
i ;
Homogenize
Cell homogenate 
(Fraction 1)
Suspend in 60 ml glycerol
Spin down nuclei at 59 000 g for one hour
Supernatant Pellet
(Fraction 2) I
Suspend in 5 ml Tris buffer (pH 7)
Homogenize
I I
Nuclear homogenate Centrifuge at 59 000 g for one hour
(Fraction 3)
Supernatant 
(Fraction 5)
Pellet 
(Fraction 4)
Figure 4. 1 Preparation of cytoplasmic and nuclear DNA 
polymerase activities from Tctrahymena pyriformis
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this time the cell membrane dissolved away but the inner nuclear 
membrane remained intact as seen under the microscope. The mixture 
was then suspended in 60 ml glycerol. Nuclei were obtained by 
centrifugation at 59 000 g for one hour. The supernatant (Fraction 2) 
contained the cytoplasmic activity. The nuclear pellet was suspended 
in 5 ml Tris-HCl buffer (Tris-HCl, MgCl2 , and KC1 10 mM each, pH 7.9) 
and homogenized. The homogenate was centrifuged at 59 000 g for one 
hour to remove unbroken nuclei. The supernatant (Fraction 5) was 
used as the nuclear preparation.
The preparation of enzyme fractions is shown in Figure 4.1. The 
DNA polymerase activity was unstable in glycerol. All experiments 
with Fraction 2 were done on fresh preparations. If necessary 
Fraction 5 was divided into several portions which were stored at —20°C.
These were then thawed and used as required. Stored in this way the 
preparations maintained their activity for about a week.
An attempt was made to prepare nuclei using concentrated sucrose 
solutions (2.4 M) instead of glycerol. Cells were harvested by 
centrifugation as described above. The cell pellet was suspended in 
30 ml sucrose (2.4 M). The cells were then broken in a motor-driven 
homogenizer until all the cells were disrupted.
The homogenized cells were then centrifuged at 59 000 g for one 
hour. The supernatant was designated Fraction 2. The pellet was 
resuspended in buffer and homogenized to break up nuclei. After 
centrifugation for one hour at 59 000 g the supernatant was used for 
assays as Fraction 5.
4.3.7 Fractionation of Tetrahymena DNA polymerase activities by DEAE-
cellulose chromatography________________
Log phase cells were harvested and resuspended in buffer (Tris- 
HCl, MgCl2 , and KC1, 10 mM each, pH 7.9). The cells were then homogenized
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in a motor-driven homogenizer to disrupt most of the cells. The 
homogenate was centrifuged at 59 000 g for one hour to remove unbroken 
cells, nuclei and mitochondria. Homogenization broke up most of the 
macronuclei of the cells. The supernatant was then fractionated 
with ammonium sulphate. The 30 to 70% ammonium sulphate pellet was 
dissolved in Tris buffer and dialysed overnight against buffer A 
(10 ml! Tris-HCl pH 7.9, 1 mM EDTA, 0.1 mM dithiothreitol, and 20% 
glycerol). The enzyme preparation was then fractionated on a DEAE- 
cellulose column (206). The dialysate was applied onto a DEAE- 
cellulose column (1 x 21.5 cm). The column was washed to remove 
unbound protein (as measured by absorbance at 280 nm). The protein 
bound to the column was then eluted with a gradient between 0.05 and 
0.8 M KC1. Fractions (3.5 ± 0.4 ml or 65 drops) were collected on an 
LKB Redirac fraction collector in the "drop" mode. Protein was 
monitored by measuring absorbance at 280 nm in a Unicam SP 1500 
spectrophotometer.
Enzyme fractions prepared by the method above were generally 
unstable. Adding BSA (100 microgram/fraction) improved the stability 
a little but not for very long. In an attempt to overcome this problem, 
I decided to carry out the fractionation of enzyme activity on the 
anion exchanger in a batch process (207). Log phase cells were 
sonicated in an USE sonicator at maximum amplitude and medium power 
in three bursts each lasting for five seconds. Between sonication 
bursts the cell mixture was allowed to cool in ice for thirty seconds. 
The sonicated cells (4 ml,l0mg/m! protein) were mixed with DEAE- 
cellulose to form a thick paste. The mixture was stirred for about 
two minutes. The ion exchanger was separated from the liquid by 
centrifugation. The supernatant was treated with a further quantity
of DEAF.-ce 1 lulosc and the exchanger again separated from the liquid.
The pellets were combined and treated with 8 ml KC1 (0.3 M in buffer 
A). After centrifugation the pellet was treated with 8 ml of more 
concentrated KC1 (0.8 M in buffer A). After centrifugation the 
pellet was discarded. The supernatants from the 0.3 M and 0.8 M salt 
treatment were dialysed overnight against buffer A.
DNA polymerase activity was determined by measuring the incorpor­
ation of (^H)TTP into acid-insoluble material. The sensitivity of 
enzyme preparations to NEM and AraCTP and the use of different 
template-primers were studied. When studying the use of synthetic 
template-primers by DNA polymerase preparations 0.1 absorbance units 
of each synthetic template-primer were used in assays instead of 
denatured calf thymus DNA. The total number of absorbance units of 
each template-primer delivered by the supplier was dissolved in water 
to give a concentration of 10 units per ml. For assays ten microlitres 
of the resulting solution were used.
4.4 Results and Discussion
4.4.1 Preliminary studies on the DNA polymerase activity in Tetrahymena
In the early stages of the work a preliminary study on the DNA 
polymerase activity of Tetrahymena was made. Figure 4.2 shows the 
effect of pH on the DNA polymerase activity of cell homogenates. In 
Tris buffer the enzyme had a broad optimum with maximal activity 
occurring at a pH of about 7.9.
The time course of the polymerase reaction is shown in Figure 4.3. 
Increasing the reaction time leads to increased incorporation of 
labelled TTP for about half an hour. After this time there is a 
decrease in the amount of label incorporated. This fall in the
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incorporation of TTP is probably due to nuclease activity. In order 
to achieve as much incorporation of label ns possible it was decided 
to incubate the enzyme preparations with TTP for twenty five minutes.
The low incorporation of labelled TTP observed in DNA polymerase
assays led to an investigation of the nuclease activity of Tetrahymena
enzyme preparations. The nuclease activity of cell homogenates is
shown in Figures 4.4 and 4.5. The high nuclease activity observed
was certainly responsible for the low polymerase activities observed.
The nuclease activity is decreased by increasing the amount of
denatured calf thymus DNA added as template-primer (Figure 4.5). I was
unable to find an agent which selectively inhibits nuclease activity
without affecting polymerase activity. There is some evidence that
the polymerase and nuclease activities are contained in the same
protein. Crerar and Pearlman observed that nuclease activity
accompanied polymerase activity in all the fractionation procedures
they used (1 0 2 ).
on DNA polymeraa« activity
The effect^of increasing the amount of denatured calf thymus DNA 
template-primer is shown in Figure 4.6. Although maximal activity 
was obtained with about 30 micrograms DNA per assay this was only 
slightly different from the activity obtained with half that amount 
of DNA per assay. For an unknown reason the amount of label incorpor­
ated decreases when more than 30 micrograms of DNA is used.
4.4.2. Terminal deoxynucleotidy 1 transferase
The DNA polymerase activities of Tetrahymena cell homogenates, 
Fraction 2, and Fraction 5 in the presence of TTP as the only 
deoxynucleotide substrate are shown in Table 4.1. The little 
activity that is observed could be due to the presence of deoxynucleo- 
tides in the enzyme preparations. In my opinion Tetrahymena does not
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Figure 4.2
Effect of pH on the DNA polymerase activity of crude homogenates of
Tetrahymena
DNA polymerase activity was determined by measuring the 
incorporation of labelled TTP into acid—insoluble material. The 
determination of enzyme activity was done as described in Section 4.3.4 
except that buffers of different pH were used as required.

Time course of the DNA polymerase reaction
DNA polymerase activity was determined by measuring the 
incorporation of TIP into acid-insoluble material as described in the 
text. The reaction was stopped with acid at different times.

Figure 4.4
Time course of the nuclease activity of Tetrahymena
Nuclease activity was measured by following the release of acid- 
soluble products from poly(dA-(methyl-3H)dT. After incubation of 
labelled polyd(A-T), buffer and enzyme extract, the reaction was 
stopped by adding TCA. After centrifugation to remove acid-insoluble 
material the radioactivity in the supernatant was counted.
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Figure 4.5
Effect of added calf thymus DNA on the nuclease activity 
of Tetrahymena cell homogenates____  _____ _ r r rt- i • t • - — ——— - '
ity
acid-
20
______ L
30
_L______ L
40 50
_±
10
Microgram DNA per assay
have a terminal deoxynucléotidyl transferase activity. Fractions 
collected during the fractionation of the DNA polymerase activity of 
Tetrahymena on DEAE-cellulose columns did not show polymerase activity
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when TTP was the only deoxynucleotide substrate. This is probably 
due to the removal of any endogenous deoxynucleotides that might have 
contributed to the small activity observed with crude preparations.
4.4.3. Fractionation of DNA polymerase activities on DEAE-cellulose
Figure 4.7 and Table 4.2 show the fractionation of DNA polymerase 
activities of Tetrahymena on DEAE-cellulose columns. Two major DNA 
polymerase activity peaks, A and B, were observed. The activities 
were eluted with 0.25 and 0.6 M salt respectively. Other smaller 
peaks which were not consistently observed in duplicate experiments 
may be associated with experimental error in the fractionation 
and assay procedures. Because of the instability of enzyme 
preparations from DEAE-cellulose columns it was not possible to 
perform meaningful studies of the effect of using different template- 
primers and inhibitors.
The fractionation of DNA polymerase on DEAE-cellulose was more 
successful when performed as a batch process. Because the process 
was done in a shorter time and with fewer steps the enzyme 
preparations did not lose their activity during fractionation. As 
the final volumes occupied by enzyme samples were much smaller than 
in the column method there was less dilution of any activity that 
might be present. As can be seen from Table 4.3 a thirty-fold 
purification of enzyme activity was achieved. This compares favourably 
with the two-fold purification achieved by the initial ammonium sulphate 
step of the column method.
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percent activity
homogenate Fraction 2 Fraction 5
Complete cocktail 1 0 0 1 00 1 0 0
TTP only 8.1 ± 1.3 2.7 ± 0.6 5.6 ± 1.4
Table 4.1 Terminal deoxynucléotidyl transferase activity of
Fraction 2 and Fraction '■
The DNA polymerase activity of the preparations was measured 
with only TTP as the deoxynucleotide substrate. Polymerase activity 
was determined by measuring the incorporation of labelled TTP into 
acid-insoluble material. The activity with only TTP as the deoxy­
nucleotide was expressed as a percentage of the DNA polymerase 
activity with all the four deoxynucleotides present in the assay 
mi xture.
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FRACTION Volume TotalProtein
( i%- ;
Total
Units
Specific activity 
nmol/min/mg protein 
x 1 0 3
Homogenate 5 29.5 91.5 3.1 ± 0.2
59 000 g 
supernatant 5.6 8 . 1 28 3.5 ± 0.3
0-30% NH4SO4 
pellet
1 . 8 2 . 8 4 1.7 ± 0.1
30-70%
NH4SO4
po 1 let
1 . 8 4.2 31 7.6 ± 0.2
Table 4 . 2  Fractionation of Tetrahymena DNA polymerase activities
Cell homogenates were centrifuged at 59 000 g and solid ammonium 
sulphate added in two steps to give final concentrations of 30% and 
70%. The pellets from the 30% and 70% ammonium sulphate cuts were 
dialysed against buffer and the DNA polymerase activity of the 
dialysate measured. The specific activity was expressed as nmoles 
TTP incorporated per minute per milligram of protein.
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Figure 4.6
Effect of increasing the amount of denatured DNA template-primer on 
_____________________DNA polymerase activities of cell homogenates.
DNA polymerase activity was determined by determining the 
amount of labelled TTP incorporated into acid-insoluble material as 
described in Section 4.3.4 of the text. The assay mixtures contained 
increasing amounts of denatured calf thymus DNA template-primer.
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Figure 4.7
Fractionation of the DNA polymerase activity of Tetrahymena 
on DEAE-cellulose
Cell homogenates were centrifuged at 59 OOOg and the supernatant 
applied onto a DEAE-ce1lulose column. The column was washed with 
buffer and then eluted with a gradient of 0.05 to 0.8 M KC1 in 
buffer. Fractions (3.5 ml) were collected using a fraction collector 
which could be set to deliver a known number of drops per fraction. 
The DNA polymerase of each fraction was measured as described in the 
text. Protein was monitored by measuring the absorbance at 280 nm.
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4.4.4. The use of synthetic template-primers by l)NA polymerase
prepa rat ions_______________________
Table 4.4 shows the use of DNA and synthetic template-primers by cell 
homogenates. In the presence of magnesium as the metal ion, maximal 
activity occurs with polyd(A-T) as the template-primer. The activity with 
polyd(A-T) is twice as high as that with denatured calf thymus DNA. 
PolyA.dT^0 was used nearly as well as denatured DNA. It is interesting 
that Tetrahymena also possessed a polymerase activity which was able 
to copy the RNA-like template, polyA, in polyA.polydT.
In the presence of manganese as the metal ion all the template- 
primers were poorly used. It may be significant that with manganese 
as the metal ion polyA.polydT was the template-primer with which all 
the preparations showed maximal activity.
The use of DNA and synthetic template-primers by enzyme fractions 
prepared by batch DEAE-cellulose fractionation is shown in Table 4.3.
The activities of the fraction that came off the exchanger in 0.3 M 
salt (fraction A) and 0.8 M salt (fraction B) were studied. Fraction 
A used denatured DNA better than all the other template-primer 
systems. Polyd(A-T) and polyA.dT^Q were poorly used by this fraction. 
PolydA.dTjo was used at a rate only slightly lower than that obtained 
with denatured DNA. PolyA.polydT was the template-primer with which 
fraction B showed the highest activity. This fraction used both 
polyA.polydT and polydA.dTio better than denatured DNA.
Table 4.5 shows the use of synthetic template-primers by 
fractions 2 and 5. In this experiment polyA.dTjg was used as the 
RNA-like template-primer. Both enzyme preparations used the RNA-like 
polyA.dTjQ at a lower rate than denatured DNA. PolydA.dT^g, which 
gave high activities with fraction 2 , was used at a lower rate than
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Table 4.3
The use of DNA and synthetic template-primers by Fraction A and B
The DNA polymerase activity of fraction A and fraction B was 
studied with DNA and synthetic polynucleotide systems as template- 
primers. The specific activity was expressed as nmoles of TTP incor­
porated per minuted per milligram of protein. The last two rows 
show ratios of activities with some of the synthetic template-primers 
to highlight differences between fraction A and B. The activity of 
the two fractions in the presence of 80 mM AraCTP is also shown.
DNA
polyd(A-T) 
polyA.polydT 
polydA.dT^o 
AraCTP
PolyA.polydT 
Ratio ______________
Polyd(A-T) 
PolyA.polydT
Ratio
l
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Specific activity:nmol/min/mg 
protein x 1 0 ^
Fraction A Fraction B
147.0 ± 0.2
23.9 ± 0.4
39.1 ± 0.3
126.0 ± 2
108.0 ± 2
1.6
131.0 ± 1
35.2 ± 0.5
195.0 + 2
163.0 ± 3
149.0 ± 3
5.5
0.3 1.2
PolydA.dTin
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Table 4.4
The use of denatured DNA and synthetic template-primers by crude 
enzyme preparations of Tetrahymena
The DNA polymerase activities of cell homogenates with denatured 
calf thymus DNA and synthetic polynucleotide systems as template- 
primers was studied. The polymerase activity with each template- 
primer was measured with magnesium or manganese as the divalent
ca t i o n .
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Specific
activity
Template-primer Metal ion nmoles/min/mg
protein x 1 0 ^
denatured DNA Mg 6 . 2  ± 0 . 2
denatured DNA Mn 1 . 1  t 0 . 2
polyA.polydT Mg 3.2 ± 0.3
polyA.polydT Mn 1.9 ± 0.4
polydA.dT jq Mg 5.1 ± 0.3
polydA.dT1 0 Mn 1 . 1  ± 0 . 2
polyd(A-T) Mg 12.6 ± 0.3
polyd(A-T) Mn 1.5 ± 0.2
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Table 4.5
The use of DNA and synthetic template-primers by 
Fractions 2 and 5 ___
The DNA polymerase activity of fraction 2 and fraction 5 was 
studied with DNA and synthetic polynucleotide systems as template- 
primers. The specific activity was expressed as nmoles of TTP 
incorporated per minute per milligram of protein. The last two rows 
show ratios of activities with some of the synthetic template- 
primers to highlight differences between fractions 2 and 5.
Specific activity nmol/min/mg protein x 103
Fraction 2 Fraction 5
DNA
polyd(A-T)
polyA.dT
polydA.dT
14.3 ± 0.3
21.0 ± 0.2
12.6 ± 0.3
22.6 ± 0.1
284.0 ± 2
237.0 ± 1
273.0 ± 3
201.0 ± 2
PolyA.dT^Q 
Ratio __________
Polyd(A-T)
0.6 1.2
PolyA.dTlQ 
Ratio ______ 0.5
10
1.3
PolydA.dT
denatured DNA by fraction 5. The lack of a clear trend in these results 
probably indicates that the two enzyme activities, sensitive and 
insensitive to NEM, are not clearly resolved in fractions 2 and 5.
Taking this into account it seems that most of the activity in the 
nuclear preparation, fraction 5, is the same as activity B. The 
enzyme activity in the cytoplasmic preparation, fraction 2 , behaves 
like activity A.
A.4.5. The effect of AraCTP and NEM on DNA polymerase activities of 
________________ preparations from Tetrahymena_______________
The effect of NEM on the DNA polymerase activities of fraction 2 
and fraction 5 is shown in Figure 4.10. In the presence of 1.5 mM NEM, 
the activity of fraction 2 iS' inhibited by 70% whereas that of fraction 
5 is inhibited by only 30%. The differences in sensitivity to NEM 
probably reflect differences in the number of sensitive sulphydryl 
groups in the two enzymes.
The activity of fraction 2 is reduced by about 90% in the presence 
of 80 mM AraCTP as shown in Figure 4.8. By contrast, this concentra­
tion of AraCTP increased the activity of fraction 5 by about 50%
(Figure 4.9). The increased activity of fraction 5 may indicate that 
this enzyme is able to use AraCTP in replicating DNA. However, this 
conclusion needs further examination in view of the observation by 
Yoshida's group that AraCTP did not support DNA synthesis by 
substituting for dCTP (166).
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Figure 4.8
Effect of AraCTP on the DNA polymerase activity 
of fraction 2 __
The DNA polymerase activity of fraction 2 was determined in the 
presence of increasing concentrations of AraCTP. The activity of 
preparations in the presence of AraCTP was expressed as a percentage 
of the activity with no inhibitor. The activity with no AraCTP added
was taken to be 1 0 0%
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Effect of AraCTP on the DNA polymerase activity of fraction 5
The DNA polymerase activity of fraction 5 was measured in the 
presence of AraCTP and expressed as a percentage of the activity 
without AraCTP added. The graph shows the percentage increase in 
activity over that obtained without AraCTP.

Effect of NEM on the DNA polymerase activities of fractions 2 and 5
The DNA polymerase activities of fractions 2 and 5 were 
determined in the presence of NEM. The activity with NEM was expressed 
as a percentage of that without the drug in the assay mixture.
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CONCI.I'S ION
Work on DNA replication in eukaryotes has been strongly 
influenced and sometimes dominated by ideas from studies on bacterial 
and viral systems. The concept of replicons, well characterised in 
the lower systems, is only poorly understood in eukaryotes. This has 
led to some confusion in the literature especially with respect to 
the problem of the initiation of DNA synthesis. It is not always 
clear whether what is referred to is the beginning of the replication 
of whole chromosomes, the initiation of individual replication units 
or the initiation of Okazaki fragments. Although it is usually 
assumed that the above are three distinct aspects in the initiation of 
DNA replication, in practice it has not been easy to observe the 
processes separately. This limits the usefulness of distinguishing 
these facets of the initiation process.
In this work 1 observed that in the presence of AraC, (methyl- 
3H)thymidine was incorporated into DNA of high molecular weight but 
that the initiation of new small molecular weight DNA was inhibited. 
When lysed cells that had been incubated with labelled thymidine were 
applied onto alkaline sucrose gradients and centrifuged, the peak of 
maximum radioactivity was recovered from fractions corresponding to 
a sedimentation coefficient of 20S. In the presence of AraC (0.5 mM) 
this peak shifted to the higher sedimentation coefficient of 30S.
This result is similar to that reported by Fridland (181) who 
observed that in human lymphoblasts, in the presence of AraC peaks 
of radioactivity were associated with progressively higher S values. 
Fridland concluded that AraC inhibited the formation of new replicons 
without affecting elongation or other steps in the replication of DNA.
By contrast Dijkwel and Wanka (1HO), working with calf liver cells, 
found that in the presence of AraC short chains of DNA accumulated.
It may be significant that the AraC concentrations used by Fridland 
(3 x 10~ 8 M) were much lower than those used by Dijkwel and Wanka 
(10'^ M) and those used in the work described in this thesis (5 x lO-  ^M). 
However, this variation could also be a reflection of differences 
between the species from which the experimental cells were obtained.
The results reported in this thesis indicate that in Tetrahymena,
AraC at the concentrations used inhibited the early stages of DNA 
synthesis. If AraC acted on DNA synthesis by reducing the rate of 
chain elongation, the sedimentation profiles of pulse-labelled DNA 
from cells treated with AraC would have shifted to lower S values 
than those observed with untreated cells. It is not possible from 
the results obtained, to state whether the initiation stage affected 
is that of whole chains, replication units or Okazaki-type fragments.
As protein synthesis was found to be insensitive to AraC it can be 
concluded that AraC does not act by inhibiting the production of the 
enzymes required for the initiation of DNA replication.
To test the conclusion arrived at here it would be necessary to 
perform pulse-chase experiments in which cells would be pulsed with 
bromodeoxyuridine and labelled thymidine followed with a chase of 
unlabelled thymidine as described by Gautschi and co-workers (209).
The density of DNA formed in the presence of AraC would then be 
analysed by equilibrium centrifugation on caesium chloride gradients.
A reduction in the density of DNA in the presence of inhibitor would 
indicate that chain elongation was inhibited whereas no change would 
indicate that elongation was not affected (181).
It does not seem that there will be an early answer to the
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1problem ot the detailed mechanism of how AraC causes cell death. 
Although there is general agreement that AraCTP is the active agent in 
causing cell death there is disagreement as to whether it is 
incorporated into DNA. Reports claiming the incorporation of AraCTP 
are not always convincing. In many cases only a tiny fraction of 
the total radioactivity in AraCTP is observed to enter into DNA.
The effect of AraC in inhibiting DNA synthesis and causing cell 
death would be expected to depend, at least in part, on the cellular 
concentration of AraC itself. The rate of transport of AraC and 
other nucleosides into cells is higher than the rate of phosphoryl­
ation (183). In this work I have described how AraC is rapidly 
deaminated to Aral) in Tetrahymena. In the presence of low concen­
trations of tetrahydrouridine the deamination of AraC by Tetrahymena 
cytidine deaminase is totally inhibited. Although the levels of AraC 
remain high in the presence of tetrahydrouridine no increase in the 
levels of the putative active agent, AraCTP, was observed. The 
levels of AraCMP and AraCDP also remained low in the presence of 
tetrahydrouridine. It appears, therefore, that phosphorylation is 
the limiting step in the incorporation of AraC into the nucleotide 
pool. The results described in this thesis indicate that the low 
incorporation of AraC into the nucleotide pool does not result from 
slow transport into cells but rather from a low rate of phosphoryl­
ation. The slow phosphorylation of AraC could be due to feedback 
inhibition of the cytidine kinase by intracellular dCTP (183).
During the course of this study it was realised that Tetrahymena 
cells were much less sensitive to the effects of AraC than mammalian 
cells. For example, whereas 0.018 mM AraC produced 20% inhibition 
of DNA synthesis as measured by thymidine incorporation in human
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leukaemic leukocytes (210), about 100 times this amount of AraC is 
required to produce detectable inhibition of thymidine incorporation 
Tetrahymena cells. It is not clear why Tetrahymena should have this 
high threshold AraC concentration before DNA synthesis and cell 
replication are affected.
Further work in this area should include more detailed study of 
the phosphorylation of AraC in target cells and the examination of the 
possibility that deamination can occur after the formation of AraCTP 
or other phosphorylated products of AraC. Since AraC is rapidly 
inactivated, in clinical use continuous infusion or multiple repeated 
doses of the drug are required to produce toxicity. It would be useful 
to synthesize and investigate the use of AraC derivatives which retain 
the cell-killing properties of AraC but 
whose amino groups are modified to make 
them poor substrates for cytidine 
deaminase. Such compounds would be 
expected to retain the chemotherapeutic 
properties of AraC and to remain in 
cells longer than the parent compound.
For example, cyclocytidine has been used t
OHcircumvent the need for continuous infusions
of AraC. This drug, another cytidine derivative, is slowly hydrolysed
cellsin and thus acts as a steady source of AraC (211). However, this drug 
has undesirable effects in addition to those observed with AraC.
The enzymology of DNA replication in eukaryotes is still in its 
early stages. Because of the lack of suitable mutants it has been 
necessary to rely on the use of synthetic template—primers and 
analyses of DNA polymerase activities during the cell cycle in
cyclocytidine
assigning biological roles to the various DNA polymerase activities 
discovered. It is generally assumed that the DNA polymerases whose 
activities rise during the S phase of the cell cycle are the ones 
involved in DNA replication. Those DNA polymerases whose activities 
remain constant throughout the cell cycle are presumed to perform 
special functions like DNA repair.
One must be careful in interpreting results obtained when using 
purified or partially purified enzyme preparations. It is always 
possible that units which are stable in vivo disintegrate during 
fractionation procedures to yield separate proteins or protein 
fragments which retain some enzyme activity. Study of the properties 
of these disordered proteins would lead to erroneous conclusions 
about the behaviour of the enzymes in intact cells. Procedures like 
salt treatment may disrupt weakly associated proteins. Disruption 
of cells could also lead to the attack of DNA polymerizing enzymes by 
proteolytic enzymes. As DNA polymerases tend to lose activity when 
protein concentration is low (206) 1 added BSA to dilute fractions to 
improve stability of the enzymes. Glycerol, dithiothreitol and 
mercaptoethanol were also added to provide further stabilisation.
In this work I attempted to study the biological function of 
Tetrahymena DNA polymerases by investigating the use of some synthetic 
template-primers by enzyme preparations from this organism. Four 
template-primer systems, denatured calf thymus DNA, polyd(A-T), 
polyA.polydT or polyA.dTjQ and polydA.dTj^ were used. The four 
enzyme fractions, the nuclear preparation (fraction 5), the cyto­
plasmic fraction (fraction 2), the activity eluted from DF.AE-cellulose 
by 0.3 M salt (fraction A) and the activity eluted from DEAK-cellulose 
by 0.8 M salt (fraction B) could use all the four template-primer
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assigning biological roles to the various DNA polymerase activities 
discovered. It is generally assumed that the DNA polymerases whose 
activities rise during the S phase of the cell cycle are the ones 
involved in DNA replication. Those DNA polymerases whose activities 
remain constant throughout the cell cycle are presumed to perform 
special functions like DNA repair.
One must be careful in interpreting results obtained when using 
purified or partially purified enzyme preparations. It is always 
possible that units which are stable in vivo disintegrate during 
fractionation procedures to yield separate proteins or protein 
fragments which retain some enzyme activity. Study of the properties 
of these disordered proteins would lead to erroneous conclusions 
about the behaviour of the enzymes in intact cells. Procedures like 
salt treatment may disrupt weakly associated proteins. Disruption 
of cells could also lead to the attack of DNA polymerizing enzymes by 
proteolytic enzymes. As DNA polymerases tend to lose activity when 
protein concentration is low (206) 1 added BSA to dilute fractions to 
improve stability of the enzymes. Glycerol, dithiothreitol and 
mercaptoethanol were also added to provide further stabilisation.
In this work I attempted to study the biological function of 
Tetrahymena DNA polymerases by investigating the use of some synthetic 
template-primers by enzyme preparations from this organism. Four 
template-primer systems, denatured calf thymus DNA, polyd(A-T), 
polyA.polydT or polyA.dT|Q .and polydA.dT.^ were used. The four 
enzyme fractions, the nuclear preparation (fraction 5), the cyto­
plasmic fraction (fraction 2), the activity eluted from DEAE-cellulose 
by O.J M salt (fraction A) and the activity eluted from DEAE-cellulose 
by 0.8 M salt (fraction B) could use all the four template-primer
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Property Fraction 2 (A) Fraction 5 (B)
Sensitivity to AraCTP Inhibited Stimulated
Sensitivity to NEM Sensitive Resistant
Preferred synthetic 
template-primer
polydA.dT^Q polyA.polydT or 
polyA.dT10
Cellular location Cytoplasm and 
nucleus ( 2 only)
Nucleus (5 only)
Salt concentration for 
elution from 
DEAE-ce1lulose
0.3 M (A only) 0.8 M (B only)
A comparison of the DNA polymerase activities 
Tetrahymena described in this thesis
systems above in incorporating TTP into acid-insoluble material. 
Fraction 2 and fraction A showed high activities with the DNA-like 
template-primers polydA.dTj« and polyd(A-T). Fraction A showed 
maximal activity with denatured calf thymus DNA whereas fraction 2 
had the highest activity with polydA.dTjQ. In contrast fraction 5 
and fraction B were able to use polyA.dTj^ and polyA.polydT respect­
ively better than polydA.dT^Q. This means that these enzyme 
preparations were able to copy the RNA-like template polyA in 
polyA.polydT of polyA.dTjQ. This finding is in disagreement with 
that of Crerar and Pearlman (102) who found that activity with 
polydA.dTjQ but not with polyA.dT|Q in the presence of magnesium as 
the metal ion. Working with crude homogenates from Tetrahymena, 
these workers found only a small activity with poly.dTjQ with 
manganese as the divalent cation.
Fraction 2 and fraction A were found to be sensitive to AraCTP 
whereas fraction 5 and fraction B showed increased activity in the 
presence of this drug. Differential sensitivity to AraCTP has also 
been observed between DNA polymerase alpha and DNA polymerase beta of 
the higher eukaryotes. DNA polymerase is found to be less sensitive 
than DNA polymerase alpha (166). On the basis of the differences 
reported alone, it would be difficult to assign specific functions to 
the enzyme activities that were studied. It would be useful to study 
the ability of these enzyme preparations to extend RNA primers in 
copying DNA-like templates as enzymes that can extend RNA primers 
would probably be DNA replication rather than repair enzymes.
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Preparation
APPENDIX I
of defined medium DYY
The following stock solutions were made:
Stock 1
D-L alanine 1500 mg 6g
L-arginine HC1 1500 mg 6g
L-asparagine H20 10 0 0 mg 4g
L-glutamic acid 2000 mg 8g
L-glutamine 500 mg 2g
Glycine 2000 mg 8g
L-histidine HC1,H20 10 0 0 mg 4g
L-isoleucine 10 0 0 mg 4g
L-leucine 10 0 0 mg 4g
L-lysine HC1 10 0 0 mg 4g
D-L methionine 1500 mg 6g
D-L phenylalanine 1500 mg 8g
L-proline 10 0 0 mg 4g
D-L serine 1500 mg 8g
D-L threonine 2000 mg 8g
L-tryptophan 750 mg 3g
D-L valine 10 0 0 mg 4g
Total 250 ml water 10 0 0
Stock 2
Guanosine 500 mg
Total: 250 mi water, add KOH to dissolve
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Stock 3
Nicotinic acid 45.0 mg
d-pantothenate Ca 37.5 mg
Thiamine HC1 25.0 mg
Riboflavine 5'P Na 22.5 mg
pyridoxamine 2 11C1 2.5 mg
D-L thioctic acid 0.5 mg
Folinic acid, Calcium salt
pyridoxal HC1 2 .5 mg
Biot in 0.05 mg
Total 250 ml
Thioctic acid should be dissolved first.
Stock 4
10280 mg K2H1'04 Total 250 ml 
Stock 5
"Salts". Add citric acid first and ensure that it is dissolved before 
adding the other salts.
A: citric acid tl20 15000 mg
B: CaCl22H20 331 mg (anhydrous 250 mg)
MgSO^ 71120 
Total 250 ml 
Stock 6
12500 mg
Fe(NH^) 2 (S04)2bH20 284 mg
ZnS04.71120 ‘)0 mg
MnSO*. 41120 32 mg
CuS04.5H20 6 mg
Co(N03)2 .bH20 10 mg
(NH4)eMo7°24•4h 2° 2 mg
Total: 100 ml adjust to pH 2.00 with cone. HC1.
All stock solutions are stored in the freezer.
M
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For one litre of medium the following amounts from stock solutions 
were used:
(1) 50 ml amino acids
(2) 25 ml guanosine
(3) 5 ml vitamins
(¿t) 1 0 ml phosphate
(5) 10 ml of both A and B
(6 ) 5 ml trace elements
The quantities were made up to one litre with water and the pH was 
adjusted to 7.1 with 20% KOH. Glucose was added to a final 
concentration of 1 g/100 ml of medium. The medium was then autoclaved 
for ten minutes at a pressure of 15 lb/sq. in.
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APPKNDIX II
Apparatus for collecting fractions from density gradients
1 . Pong injection needle
2. Centrifuge tube
3. Rubber stopper
A. Outlet to receiving tube
5 . Inlet from air supply
6 . Perspex plate to keep rubber stopper in place
7. Rubber band
8 . Perspex stand
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APPENDIX III
Calculation of sedimentation coefficients
The sedimentation coefficient, s, is defined as the sedimentation 
velocity in unit field strength, that is
where r is the distance of the molecule from the axis or rotation at 
time t and OJ is the angular velocity in radians/second. Sedimentation 
coefficients determined in density gradient media are converted to 
standard coefficients which would be obtained for a given molecule 
in water at 20°C (s20 w)• The s2o>w of a particle sedimenting at a 
temperature T, through a medium m of density -j. and viscosity 5x,m 
is given by
ol r
s dt ( 1 )
s ( 2 )
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Integration of (2) yields
s.
2 0,w t°2dt . "H m l-'Op - ^°20;w
^  320,wl^p- >°T,m )
(3)
Assuming that acceleration and deceleration times are negligible the
2
time integral on the left becomes S2o,wCiJt where t is the total time 
of the sedimentation run. If the gradient is linear the radius may be 
expressed in terms of the sucrose concentration (Z)
where Z0 is the extrapolated concentration at the centre of rotation. 
The right side of (3) can be expressed solely in terms of concentration 
and may be evaluated if the temperature, particle density and ZD are 
known. The values of this integral for particle densities of 1.1 to
1.9 g/ml, temper; tures of 0°, 59, and 20°C and for Zc values from 5 
to - UHJ have been computed by McEwen.
If during centrifugation a particle travels from Zy at t^  to 
7-2 at t^  then equation (3) can be written as
of the particle density, temperature and Z_. ZQ is evaluated from
Z - Zo
(4)
dr T
(5)
1 (Z.) and I,, , are obtained from McEwen's tables from a knowledge
1 y'.j)
the dimensions of the rotor used.
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top of sucrose gradient
minimum radius R .nun
maximum radius R
centre of rotation
A typical calculation for the SW25.2 rotor is shown below.
(A) First the distance of each fraction from the centre of rotation 
was evaluated. If 25 fractions are collected and each occupies
R - R .max min
25
7.53
25
0.30 cm ( 6 )
r for each fraction can now be obtained.x
(B) Z is now evaluated usingo
Z, r l x Z r x 1
(7)
7 is taken to be 5% and r^  8 cm. Evaluation Zq for any Z, R pair 
yields 11.67.
(c) Knowing Z I. values are now looked up from McEwen's tables. AO IX/
particle density of 1.4 is assumed. For ease of use a plot of Z^
against I, . is made.(x)
(D) 1. . - l-_ is calculated lor each fraction.(x) 5Z
Finally sedimentation coefficients are calculated from
2 0 , w I(x) " l 57.
Sucrose concentration (%)
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Fraction rx(cm) z X zo IX !x " *4% S( X 10 13)
1 8 5 -11.67 - - -
2 8.3 5.625 -11.67 0 . 8 8 0.2349 4.7
3 8 .6 6.25 -11.67 0.98 0.3349 6.7
4 8.9 6.875 -11.67 1.06 0.4149 8.3
5 9.2 7.5 -11.67 1 . 16 0.5149 10.3
6 9.5 8.125 -11.67 1 . 2 2 0.5749 11.5
7 9.8 8.75 -11.67 1.32 0.6749 13.5
8 1 0 . 1 9.375 -11.67 1.42 0.7749 15.5
9 10.4 1 0 . 0 -11.67 1.5 0.8549 17.1
1 0 10.7 10.625 -11.67 1.58 0.9349 18.7
1 1 1 1 . 0 11.25 -11.67 1 . 6 6 1.0149 20.3
1 2 11.3 11.875 -11.67 1.75 1.1049 2 2 . 1
13 1 1 . 6 12.5 -11.67 1.83 1.1849 23.7
14 11.9 13.125 -11.67 1.91 1.2649 25.3
15 1 2 . 2 13.75 -11.67 2 . 0 1.3549 27.1
16 12.5 14.375 -11.67 2 . 1 1.4549 29.1
17 1 2 . 8 15.0 -11.67 2.18 1.5349 30.7
18 13.1 15.625 -11.67 2.26 1.6149 32.3
19 13.4 16.25 -11.67 2.34 1.6949 33.9
20 13.7 16.875 -11.67 2.45 1.8049 36.1
2 1 14.0 17.5 -11.67 2.53 1.8849 37.7
22 14.3 18.125 -11.67 2.62 1.9749 39.5
2 3 14.6 18.75 -11.67 2.70 2.0549 41.1
24 14.9 19.375 -11.67 2.82 2.1749 43.5
25 15.1 2 0 . 0 -11.69 2.93 2.2849 45.7
16 4
Calculation of counts for each rad i onuc 1 ide in double-isotope experiments.
APPENDIX IV
When measuring radioactivity in a sample containing two radio­
nuclides each of the radionuclides contributes to the scintillations 
and produces pulses. Two counting channels are required to separate 
the pulses from each radionuclide, although each can produce counts 
in both channels. If the counting efficiencies of each radionuclide 
in each channel are known the activity of each of the two radionuclides 
can be calculated (2 0 8).
The contribution of each isotope to the total counts observed 
was evaluated from the simultaneous equations given below.
c 14c counts in sample
H 3h counts in sample
C 1
u c efficiency in red channe1
C 2
1Ac efficiency in green channel
hl 3.1 efficiency in red channel
h 2
3h efficiency in green channe1
N1
total counts observed in red channel
N2
total counts observed in green channel
N1
* C(cj) + H(hj) (l)
N2
- C(c2) + H(h2) (2 )
Solving for C and H we have
N1
- N2 (h,/h2) (3)
C1
- c2 (hl/h2)
11
N2
- N 1 (c1 /c2) (4)
- h^c^/Cj)
1 14when all the H counts are excluded from the C channel
the equations become
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N1 = C(cl>
N2 = C(c2) + H(h2)
Solving these we have
(5)
( 6 )
C
li
Nt/C
1
N2 " C(C2)
h2
(7)
( 8)
The efficiencies Cj, C,,, hj, and h2 were determined
14 3by measuring the radioactivity of C and H standards 
in both the red and the green channel.
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